<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02146365</url>
  </required_header>
  <id_info>
    <org_study_id>VAC-011</org_study_id>
    <nct_id>NCT02146365</nct_id>
  </id_info>
  <brief_title>Nasopharyngeal Carriage Study in Healthy Kenyan Toddlers</brief_title>
  <official_title>A Prospective Study to Assess the Nasopharyngeal Carriage of Streptococcus Pneumoniae (SPn), Long Term Safety and Immune Persistence in Healthy Kenyan PCV-Primed Toddlers (12-15 Months of Age) Who Received a Whole Cell Pneumococcal Vaccine (PATH-wSP) Compared to Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PATH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PATH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluated the change in nasopharyngeal carriage (NPC) of Streptococcus pneumoniae
      (SPn), hypothesizing that it would be reduced post-vaccination with Streptococcus pneumoniae
      whole cell vaccine with aluminum hydroxide adjuvant (PATH-wSP) and that PATH-wSP would remain
      safe and well-tolerated over the course of the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study enrolled healthy Kenyan toddlers (12-15 months of age) who participated in the
      randomized control trial of VAC-010 (NCT02097472), as well as healthy toddlers aged 12 to 15
      months who had not participated in the VAC-010 Study. All participants must have received a
      primary dose of pneumococcal conjugate vaccine (PCV) per local practice prior to enrollment
      in either VAC-010 or VAC-011. No treatments were administered during this study.

      The study consisted of the following four groups:

      Participants who were randomized in study VAC-010 (2:2:1 ratio), defined according to the
      treatment received in VAC-010:

        -  1. PATH-wSP + Booster

        -  2. PATH-wSP Only

        -  3. Booster Only

      Participants who did not participate in VAC-010:

        -  4. No Intervention

      Each group consisted of 2 cohorts of participants, Cohort 1 (300 µg PATH-wSP) and Cohort 2
      (600 µg PATH-wSP). Enrollment into Cohorts 1 and 2 occurred sequentially; participants in
      groups 3 and 4 who did not receive PATH-wSP were also enrolled over time and allocated into
      one of the two cohorts (300 and 600 µg) in order to control for potential seasonal variation
      in the NPC of S. pneumoniae.

      Each participant completed a total of 5 scheduled visits. For toddlers enrolled
      simultaneously in VAC-010, visits corresponded to enrollment (Baseline) and 4, 8, 12, and 24
      weeks post final vaccination in VAC-010. For toddlers in the No Intervention group, the first
      visit corresponded to Baseline and the second to fifth visits corresponded to 12, 16, 20, and
      32 weeks later. Nasopharyngeal swabs were taken at each visit following World Health
      Organization (WHO) guidelines for analysis of nasopharyngeal burden.

      Treatments received during VAC-010 included:

        -  PATH-wSP: Streptococcus pneumoniae whole cell vaccine with aluminum hydroxide adjuvant

        -  Synflorix™ booster vaccine: pneumococcal polysaccharide conjugate vaccine (adsorbed)

        -  Pentavac booster vaccine: diphtheria, tetanus, pertussis (Whole Cell), hepatitis B
           (recombinant deoxyribonucleic acid [rDNA]) and Haemophilus influenzae type b conjugate
           vaccine (adsorbed).

        -  Saline control
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 25, 2014</start_date>
  <completion_date type="Actual">February 18, 2016</completion_date>
  <primary_completion_date type="Actual">February 18, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of Streptococcus Pneumoniae in Nasopharynx</measure>
    <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
    <description>The prevalence of Streptococcus pneumoniae (SPn) in the nasopharynx was measured by the number (and percentage) of participants positive for SPn detected by quantitative polymerase chain reaction (qPCR) from nasopharyngeal swabs taken at each study visit.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only plus non-interventional participants enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only plus non-interventional participants enrolled during Cohort 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Density of Streptococcus Pneumoniae in the Nasopharynx</measure>
    <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
    <description>The density of Streptococcus pneumoniae (SPn) in the nasopharynx was measured by the number of autolysin (LytA) gene copies detected by quantitative polymerase chain reaction (qPCR) from nasopharyngeal swabs taken at each study visit.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration (GMC) of Immunoglobulin G (IgG) Antibodies Against Pneumococcal Proteins</measure>
    <time_frame>Baseline (Week 0), 4 weeks post-vaccination 2 (Week 12), and 6 months post-vaccination 2 (Week 32).</time_frame>
    <description>Immunogenicity was evaluated based on the following assays:
Immunoglobulin (IgG) response to pneumolysoid [L460D] and pneumococcal surface protein A family 1 [PspA-Fam1] was measured by enzyme-linked immunosorbent assay (ELISA).
IgG response to the following pneumococcal proteins was measured using the Meso Scale Discovery (MSD) platform:
L460D
PspA-Fam1
Pneumococcal histidine triad D (PhtD)
Boston Children's Hospital protein 785 (BCH0785)
Serine threonine kinase protein (StkP)
Pneumococcal choline-binding protein A (PcpA)
Streptococcus pneumonia whole cell antigen (SPWCA)
Pneumococcal iron uptake protein A (PiuA)
Pneumococcal iron acquisition protein A (PiaA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration Ratios of Immunoglobulin G (IgG) Antibodies Against Pneumococcal Proteins for PATH-wSP Groups Versus the Booster Only Group</measure>
    <time_frame>Week 32</time_frame>
    <description>Data reported are the geometric mean concentration at 6 months post-vaccination 2 (Week 32) for each PATH-wSP group divided by the Booster (Synflorix and Pentavax)-only group (N=38). Immunogenicity was evaluated based on the following assays:
Immunoglobulin (IgG) response to pneumolysoid (L460D) and pneumococcal surface protein A family 1 (PspA-Fam1) was measured by enzyme-linked immunosorbent assay (ELISA).
IgG response to the following pneumococcal proteins was measured using the Meso Scale Discovery (MSD) platform:
L460D
PspA-Fam1
Pneumococcal histidine triad D (PhtD)
Boston Children's Hospital protein 785 (BCH0785)
Serine threonine kinase protein (StkP)
Pneumococcal choline-binding protein A (PcpA)
Streptococcus pneumonia whole cell antigen (SPWCA)
Pneumococcal iron uptake protein A (PiuA)
Pneumococcal iron acquisition protein A (PiaA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Change of Immunoglobulin G (IgG) Antibodies Against Pneumococcal Proteins</measure>
    <time_frame>Baseline and Week 32</time_frame>
    <description>Immunogenicity was evaluated based on the following assays:
IgG response to pneumolysoid [L460D] and pneumococcal surface protein A family 1 [PspA-Fam1] was measured by enzyme-linked immunosorbent assay (ELISA).
IgG response to the following pneumococcal proteins was measured using the Meso Scale Discovery (MSD) platform:
L460D
PspA-Fam1
Pneumococcal histidine triad D (PhtD)
Boston Children's Hospital protein 785 (BCH0785)
Serine threonine kinase protein (StkP)
Pneumococcal choline-binding protein A (PcpA)
Streptococcus pneumonia whole cell antigen (SPWCA)
Pneumococcal iron uptake protein A (PiuA)
Pneumococcal iron acquisition protein A (PiaA)
The fold-change was calculated as the 6-month post-vaccination (Week 32) IgG response divided by the Baseline IgG response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Meeting Seroresponse Fold-Rise Categories at 6 Months Post Vaccination 2</measure>
    <time_frame>Baseline and Week 32</time_frame>
    <description>The percentage of participants with a seroresponse, defined as a ≥ 2, ≥ 3, and ≥ 4 fold-rise above Baseline in IgG antibody levels against Pneumococcal proteins. Fold-rise was calculated as the 6-month post-vaccination (Week 32) IgG response divided by the Baseline IgG level.
Immunogenicity was evaluated based on the following assays:
IgG response to pneumolysoid [L460D] and pneumococcal surface protein A family 1 [PspA-Fam1] was measured by enzyme-linked immunosorbent assay (ELISA).
IgG response to the following pneumococcal proteins was measured using the Meso Scale Discovery (MSD) platform:
L460D
PspA-Fam1
Pneumococcal histidine triad D (PhtD)
Boston Children's Hospital protein 785 (BCH0785)
Serine threonine kinase protein (StkP)
Pneumococcal choline-binding protein A (PcpA)
Streptococcus pneumonia whole cell antigen (SPWCA)
Pneumococcal iron uptake protein A (PiuA)
Pneumococcal iron acquisition protein A (PiaA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Neutralizing Antibody Response to Pneumolysin</measure>
    <time_frame>Baseline (Week 0) and 6 months post-vaccination 2 (Week 32)</time_frame>
    <description>Neutralizing antibody responses to pneumolysin were assessed at Baseline and 6 months post vaccination 2 using an in vitro toxin neutralization assay that measures the ability of antibodies to neutralize wild-type pneumolysin-induced lysis of rabbit red blood cells.
Each sample was categorized as negative (&lt; 1/20 dilution) or positive (with titer between 1/20 and 1/320 dilution). Responses at higher dilutions indicate higher levels of neutralizing antibodies to pneumolysin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events (AE)</measure>
    <time_frame>32 weeks; for participants enrolled concurrently in Study VAC-010 adverse events were collected after the last VAC-010 visit through to Week 32.</time_frame>
    <description>An AE was defined as any untoward, undesired, or unplanned event in the form of signs, symptoms, disease, or laboratory or psychological/physiologic observations occurring in a person in a clinical study. The AEs collected in this non-interventional study were those that remained open after the last visit in the VAC-010 Study, those attributed to study vaccine in VAC-010 with onset after the participant exited VAC-010, those that were related to a VAC-011 procedure (i.e. blood draw, nasal swab sample), and all serious adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Streptococcus Pneumoniae Serotype 11A/D/E [11A] in the Nasopharynx</measure>
    <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
    <description>Nasopharyngeal samples were further analyzed for the prevalence of specific Streptococcus pneumoniae serotypes by microarray. The number of participants with a positive result for SPn serotype 11A/D/E [11A] is reported.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Streptococcus Pneumoniae Serotype 13 in the Nasopharynx</measure>
    <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
    <description>Nasopharyngeal samples were further analyzed for the prevalence of specific Streptococcus pneumoniae serotypes by microarray. The number of participants with a positive result for SPn serotype 13 is reported.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Streptococcus Pneumoniae Serotype 15A in the Nasopharynx</measure>
    <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
    <description>Nasopharyngeal samples were further analyzed for the prevalence of specific Streptococcus pneumoniae serotypes by microarray. The number of participants with a positive result for SPn serotype 15A is reported.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Streptococcus Pneumoniae Serotype 15B/C [15B] in the Nasopharynx</measure>
    <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
    <description>Nasopharyngeal samples were further analyzed for the prevalence of specific Streptococcus pneumoniae serotypes by microarray. The number of participants with a positive result for SPn serotype 15B/C [15B] is reported.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Streptococcus Pneumoniae Serotype 19A in the Nasopharynx</measure>
    <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
    <description>Nasopharyngeal samples were further analyzed for the prevalence of specific Streptococcus pneumoniae serotypes by microarray. The number of participants with a positive result for SPn serotype 19A is reported.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Streptococcus Pneumoniae Serotype 19F in the Nasopharynx</measure>
    <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
    <description>Nasopharyngeal samples were further analyzed for the prevalence of specific Streptococcus pneumoniae serotypes by microarray. The number of participants with a positive result for SPn serotype 19F is reported.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Streptococcus Pneumoniae Serotype 3 in the Nasopharynx</measure>
    <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
    <description>Nasopharyngeal samples were further analyzed for the prevalence of specific Streptococcus pneumoniae serotypes by microarray. The number of participants with a positive result for SPn serotype 3 is reported.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Streptococcus Pneumoniae Serotype 35B in the Nasopharynx</measure>
    <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
    <description>Nasopharyngeal samples were further analyzed for the prevalence of specific Streptococcus pneumoniae serotypes by microarray. The number of participants with a positive result for SPn serotype 35B is reported.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Streptococcus Pneumoniae Serotype 6A/B [6A] in the Nasopharynx</measure>
    <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
    <description>Nasopharyngeal samples were further analyzed for the prevalence of specific Streptococcus pneumoniae serotypes by microarray. The number of participants with a positive result for SPn serotype 6A/B [6A] is reported.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Streptococcus Pneumoniae Serotype NT4b in the Nasopharynx</measure>
    <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
    <description>Nasopharyngeal samples were further analyzed for the prevalence of specific Streptococcus pneumoniae serotypes by microarray. The number of participants with a positive result for SPn serotype NT4b is reported.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Density of Streptococcus Pneumoniae Serotype 11A/D/E [11A] in the Nasopharynx</measure>
    <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
    <description>The density of Streptococcus pneumoniae serotype 11A/D/E [11A] in the nasopharynx was measured by the number of LytA gene copies detected by microarray from nasopharyngeal swabs taken at each study visit.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Density of Streptococcus Pneumoniae Serotype 13 in the Nasopharynx</measure>
    <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
    <description>The density of Streptococcus pneumoniae serotype 13 in the nasopharynx was measured by the number of LytA gene copies detected by microarray from nasopharyngeal swabs taken at each study visit.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Density of Streptococcus Pneumoniae Serotype 15A in the Nasopharynx</measure>
    <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
    <description>The density of Streptococcus pneumoniae serotype 15A in the nasopharynx was measured by the number of LytA gene copies detected by microarray from nasopharyngeal swabs taken at each study visit.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Density of Streptococcus Pneumoniae Serotype 15B/C [15B] in the Nasopharynx</measure>
    <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
    <description>The density of Streptococcus pneumoniae serotype 15B/C [15B] in the nasopharynx was measured by the number of LytA gene copies detected by microarray from nasopharyngeal swabs taken at each study visit.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Density of Streptococcus Pneumoniae Serotype 19A in the Nasopharynx</measure>
    <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
    <description>The density of Streptococcus pneumoniae serotype 19A in the nasopharynx was measured by the number of LytA gene copies detected by microarray from nasopharyngeal swabs taken at each study visit.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Density of Streptococcus Pneumoniae Serotype 19F in the Nasopharynx</measure>
    <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
    <description>The density of Streptococcus pneumoniae serotype 19F in the nasopharynx was measured by the number of LytA gene copies detected by microarray from nasopharyngeal swabs taken at each study visit.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Density of Streptococcus Pneumoniae Serotype 3 in the Nasopharynx</measure>
    <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
    <description>The density of Streptococcus pneumoniae serotype 3 in the nasopharynx was measured by the number of LytA gene copies detected by microarray from nasopharyngeal swabs taken at each study visit.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Density of Streptococcus Pneumoniae Serotype 35B in the Nasopharynx</measure>
    <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
    <description>The density of Streptococcus pneumoniae serotype 35B in the nasopharynx was measured by the number of LytA gene copies detected by microarray from nasopharyngeal swabs taken at each study visit.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Density of Streptococcus Pneumoniae Serotype 6A/B [6A] in the Nasopharynx</measure>
    <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
    <description>The density of Streptococcus pneumoniae serotype 6A/B [6A] in the nasopharynx was measured by the number of LytA gene copies detected by microarray from nasopharyngeal swabs taken at each study visit.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Density of Streptococcus Pneumoniae Serotype NT4b in the Nasopharynx</measure>
    <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
    <description>The density of Streptococcus pneumoniae serotype NT4b in the nasopharynx was measured by the number of LytA gene copies detected by microarray from nasopharyngeal swabs taken at each study visit.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
  </secondary_outcome>
  <number_of_groups>8</number_of_groups>
  <enrollment type="Actual">297</enrollment>
  <condition>Pneumococcal Disease</condition>
  <arm_group>
    <arm_group_label>PATH-wSP 300 µg + Booster</arm_group_label>
    <description>Toddlers who enrolled in Cohort 1 of Study VAC-010 and received 300 µg PATH-wSP plus the two booster vaccines (Synflorix and Pentavac) followed by a 2nd injection of 300 µg PATH-wSP 8 weeks later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PATH-wSP 300 µg Only</arm_group_label>
    <description>Toddlers who enrolled in Cohort 1 of Study VAC-010 and received 300 µg PATH-wSP and 2 saline injections followed by a 2nd injection of 300 µg PATH-wSP 8 weeks later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PATH-wSP 600 µg + Booster</arm_group_label>
    <description>Toddlers who enrolled in Cohort 2 of Study VAC-010 and received 600 µg PATH-wSP plus the two booster vaccines (Synflorix and Pentavac) followed by a 2nd injection of 600 µg PATH-wSP 8 weeks later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PATH-wSP 600 µg Only</arm_group_label>
    <description>Toddlers who enrolled in Cohort 2 of Study VAC-010 and received 600 µg PATH-wSP and 2 saline injections followed by a 2nd injection of 600 µg PATH-wSP 8 weeks later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Booster Only (300 µg)</arm_group_label>
    <description>Toddlers who enrolled in Cohort 1 of Study VAC-010 and received one saline injection and the two booster vaccines (Synflorix and Pentavac) followed by a 2nd saline injection 8 weeks later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Booster Only (600 µg)</arm_group_label>
    <description>Toddlers who enrolled in Cohort 2 of Study VAC-010 and received one saline injection and the two booster vaccines (Synflorix and Pentavac) followed by a 2nd saline injection 8 weeks later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Intervention (300 µg)</arm_group_label>
    <description>Toddlers who enrolled during Cohort 1 who did not participate in Study VAC-010 and did not receive either PATH-wSP or either of the booster vaccines (Pentavac or Synflorix).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Intervention (600 µg)</arm_group_label>
    <description>Toddlers who enrolled during Cohort 2 who did not participate in Study VAC-010 and did not receive either PATH-wSP or either of the booster vaccines (Pentavac or Synflorix).</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Nasal swab sample and blood draw
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy PCV- primed Kenyan toddlers; some of whom have participated in VAC-010 (n=250) and
        some of whom have not (n=50)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - For Toddlers Enrolled in VAC-010 (NCT02097472):

          -  Randomization in VAC-010.

          -  Subject's parent must provide voluntary written informed consent for subject to
             participate in the study, is fully capable of comprehending and complying with study
             requirements and procedures, able and willing to return for all scheduled follow-up
             visits, and has expressed availability for the required study period, with access to a
             consistent means of telephone contact. An illiterate parent will require an impartial
             witness to be present during consenting process to include discussing the consent
             form, verbal consent and thumb-printing.

          -  Subject has not completed his or her final vaccination in VAC-010.

        For Toddlers NOT Enrolled in VAC-010 (PCV-primed-only cohort):

          -  Healthy Kenyan toddlers between 12 to 15 (inclusive) months of age who have completed
             their primary Expanded Programme on Immunization (EPI) vaccines, with the exception
             that the birth dose of oral polio vaccine is not required.

          -  Subjects who have not received a PCV booster following primary PCV series.

          -  Subject's parent must provide voluntary written informed consent for subject to
             participate in the study, is fully capable of comprehending and complying with study
             requirements and procedures, able and willing to return for all scheduled follow-up
             visits, and has expressed availability for the required study period, with access to a
             consistent means of telephone contact. An illiterate parent will require an impartial
             witness to be present during consenting process to include discussing the consent
             form, verbal consent and thumb-printing.

          -  Subjects who were not born premature, had a birth weight of &gt; 2.5 kg, and who have a
             weight-to-height Z-score of ≥ -2 at the time of enrollment.

        Exclusion Criteria:

        - For Toddlers NOT enrolled in VAC-010 (PCV-primed only):

          -  Use of any investigational or non-registered drug within 90 days prior to screening,
             or planned during the course of study participation.

          -  Immunosuppression or immunodeficiency (inclusive of human immunodeficiency virus
             [HIV]) by medical history (inclusive of possible HIV through maternal fetal transfer
             at time of birth or through breast milk).

          -  Chronic, clinically significant pulmonary, cardiovascular, hepatobiliary,
             gastrointestinal, renal, neurological, or hematological functional abnormality or
             major congenital defects or illness that requires medical therapy, by medical history
             or clinical assessment. This includes abnormal vital signs as assessed by toxicity
             scoring.

          -  Any medical or social condition that in the opinion of the investigator may interfere
             with the study objectives, pose a risk to the study subject, or prevent the subject
             from completing the study.

          -  An employee (or first degree relative of employee) of the Sponsor, the Clinical
             Research Organization (CRO), the investigator or any site personnel.

          -  Disorders that required chronic administration (defined as more than 14 consecutive
             days) of immunosuppressants or other immune-modifying drugs within the 6 months prior
             to enrollment. An immunosuppressant dose of glucocorticoid will be defined as a
             systemic dose &gt;10 mg of prednisone (adult dosage) adjusted for equivalent dosing in
             toddlers by weight. The use of topical glucocorticoids will be permitted.

          -  Administration of immunoglobulins and/or any blood products within the 6 months
             preceding enrollment in the study; or anticipation of such administration during the
             study period.

          -  History of meningitis, seizures or any neurological disorder.

          -  Subject who has evidence of congenital abnormality or developmental delay.

          -  Any evidence of fetal alcohol syndrome or history of alcohol abuse in mother during
             pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>15 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nekoye Otsyula, MB ChB MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kenya Medical Research Institute/Walter Reed Project</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kenya Medical Research Institute/Walter Reed Project</name>
      <address>
        <city>Kisumu</city>
        <zip>40100</zip>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 21, 2014</study_first_submitted>
  <study_first_submitted_qc>May 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2014</study_first_posted>
  <results_first_submitted>September 12, 2018</results_first_submitted>
  <results_first_submitted_qc>February 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 17, 2020</results_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study enrolled healthy Kenyan toddlers who participated in the randomized control trial VAC-010 (NCT02097472) whose parents provided consent to participate in VAC-011. In addition, 50 healthy toddlers who did not participate in the VAC-010 study were enrolled from the community as a pneumococcal conjugate vaccine (PCV)-primed-only open cohort.</recruitment_details>
      <pre_assignment_details>Participants were enrolled sequentially into Cohort 1 (PATH-wSP 300 µg or control) and Cohort 2 (PATH-wSP 600 µg or control).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PATH-wSP 300 µg + Booster</title>
          <description>Toddlers who enrolled in Cohort 1 of Study VAC-010 and received 300 µg PATH-wSP plus the two booster vaccines (Synflorix and Pentavac) followed by a 2nd injection of 300 µg PATH-wSP 8 weeks later.</description>
        </group>
        <group group_id="P2">
          <title>PATH-wSP 300 µg Only</title>
          <description>Toddlers who enrolled in Cohort 1 of Study VAC-010 and received 300 µg PATH-wSP and 2 saline injections followed by a 2nd injection of 300 µg PATH-wSP 8 weeks later.</description>
        </group>
        <group group_id="P3">
          <title>PATH-wSP 600 µg + Booster</title>
          <description>Toddlers who enrolled in Cohort 2 of Study VAC-010 and received 600 µg PATH-wSP plus the two booster vaccines (Synflorix and Pentavac) followed by a 2nd injection of 600 µg PATH-wSP 8 weeks later.</description>
        </group>
        <group group_id="P4">
          <title>PATH-wSP 600 µg Only</title>
          <description>Toddlers who enrolled in Cohort 2 of Study VAC-010 and received 600 µg PATH-wSP and 2 saline injections followed by a 2nd injection of 600 µg PATH-wSP 8 weeks later.</description>
        </group>
        <group group_id="P5">
          <title>Booster Only (300 µg)</title>
          <description>Toddlers who enrolled in Cohort 1 of Study VAC-010 and received one saline injection and the two booster vaccines (Synflorix and Pentavac) followed by a 2nd saline injection 8 weeks later.</description>
        </group>
        <group group_id="P6">
          <title>Booster Only (600 µg)</title>
          <description>Toddlers who enrolled in Cohort 2 of Study VAC-010 and received one saline injection and the two booster vaccines (Synflorix and Pentavac) followed by a 2nd saline injection 8 weeks later.</description>
        </group>
        <group group_id="P7">
          <title>No Intervention (300 µg)</title>
          <description>Toddlers who enrolled during Cohort 1 who did not participate in Study VAC-010 and did not receive either PATH-wSP or either of the booster vaccines (Pentavac or Synflorix).</description>
        </group>
        <group group_id="P8">
          <title>No Intervention (600 µg)</title>
          <description>Toddlers who enrolled during Cohort 2 who did not participate in Study VAC-010 and did not receive either PATH-wSP or either of the booster vaccines (Pentavac or Synflorix).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="50"/>
                <participants group_id="P4" count="50"/>
                <participants group_id="P5" count="24"/>
                <participants group_id="P6" count="25"/>
                <participants group_id="P7" count="25"/>
                <participants group_id="P8" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="43"/>
                <participants group_id="P4" count="41"/>
                <participants group_id="P5" count="22"/>
                <participants group_id="P6" count="24"/>
                <participants group_id="P7" count="25"/>
                <participants group_id="P8" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to Comply with Protocol</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PATH-wSP 300 µg + Booster</title>
          <description>Toddlers who enrolled in Cohort 1 of Study VAC-010 and received 300 µg PATH-wSP plus the two booster vaccines (Synflorix and Pentavac) followed by a 2nd injection of 300 µg PATH-wSP 8 weeks later.</description>
        </group>
        <group group_id="B2">
          <title>PATH-wSP 300 µg Only</title>
          <description>Toddlers who enrolled in Cohort 1 of Study VAC-010 and received 300 µg PATH-wSP and 2 saline injections followed by a 2nd injection of 300 µg PATH-wSP 8 weeks later.</description>
        </group>
        <group group_id="B3">
          <title>PATH-wSP 600 µg + Booster</title>
          <description>Toddlers who enrolled in Cohort 2 of Study VAC-010 and received 600 µg PATH-wSP plus the two booster vaccines (Synflorix and Pentavac) followed by a 2nd injection of 600 µg PATH-wSP 8 weeks later.</description>
        </group>
        <group group_id="B4">
          <title>PATH-wSP 600 µg Only</title>
          <description>Toddlers who enrolled in Cohort 2 of Study VAC-010 and received 600 µg PATH-wSP and 2 saline injections followed by a 2nd injection of 600 µg PATH-wSP 8 weeks later.</description>
        </group>
        <group group_id="B5">
          <title>Booster Only (Both Cohorts)</title>
          <description>Toddlers who enrolled in Cohort 1 or Cohort 2 of Study VAC-010 and received one saline injection and the two booster vaccines (Synflorix and Pentavac) followed by a 2nd saline injection 8 weeks later.</description>
        </group>
        <group group_id="B6">
          <title>No Intervention</title>
          <description>Toddlers who enrolled during Cohort 1 or Cohort 2 who did not participate in Study VAC-010 and did not receive either PATH-wSP or either of the booster vaccines (Pentavac or Synflorix).</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
            <count group_id="B2" value="49"/>
            <count group_id="B3" value="50"/>
            <count group_id="B4" value="50"/>
            <count group_id="B5" value="49"/>
            <count group_id="B6" value="50"/>
            <count group_id="B7" value="297"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.2" spread="1.1"/>
                    <measurement group_id="B2" value="13.0" spread="1.1"/>
                    <measurement group_id="B3" value="13.3" spread="1.1"/>
                    <measurement group_id="B4" value="13.5" spread="1.2"/>
                    <measurement group_id="B5" value="13.1" spread="1.0"/>
                    <measurement group_id="B6" value="13.3" spread="1.2"/>
                    <measurement group_id="B7" value="13.2" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="31"/>
                    <measurement group_id="B7" value="157"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Luhya</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Luo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="45"/>
                    <measurement group_id="B5" value="46"/>
                    <measurement group_id="B6" value="48"/>
                    <measurement group_id="B7" value="274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Prevalence of Streptococcus Pneumoniae in Nasopharynx</title>
        <description>The prevalence of Streptococcus pneumoniae (SPn) in the nasopharynx was measured by the number (and percentage) of participants positive for SPn detected by quantitative polymerase chain reaction (qPCR) from nasopharyngeal swabs taken at each study visit.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only plus non-interventional participants enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only plus non-interventional participants enrolled during Cohort 2</description>
        <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
        <population>The Nasopharyngeal Carriage (NPC) population included enrolled participants with at least one post-enrollment swab measurement not associated with a protocol violation that may have interfered with the assessment of NPC outcomes. VAC-010 participants who did not receive both vaccinations were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined PATH–wSP 300 µg</title>
            <description>All participants who received PATH–wSP 300 µg, including participants in the PATH-wSP 300 µg + Booster and participants in the PATH-wSP 300 µg Only treatment groups.</description>
          </group>
          <group group_id="O2">
            <title>Combined Control (300 µg)</title>
            <description>Participants enrolled during Cohort 1 who received booster-only or no intervention.</description>
          </group>
          <group group_id="O3">
            <title>Combined PATH-wSP 600 µg</title>
            <description>All participants who received PATH–wSP 600 µg, including participants in the PATH-wSP 600 µg + Booster and participants in the PATH-wSP 600 µg Only treatment groups.</description>
          </group>
          <group group_id="O4">
            <title>Combined Control (600 µg)</title>
            <description>All participants enrolled during Cohort 2 who received booster-only or no intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Streptococcus Pneumoniae in Nasopharynx</title>
          <description>The prevalence of Streptococcus pneumoniae (SPn) in the nasopharynx was measured by the number (and percentage) of participants positive for SPn detected by quantitative polymerase chain reaction (qPCR) from nasopharyngeal swabs taken at each study visit.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only plus non-interventional participants enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only plus non-interventional participants enrolled during Cohort 2</description>
          <population>The Nasopharyngeal Carriage (NPC) population included enrolled participants with at least one post-enrollment swab measurement not associated with a protocol violation that may have interfered with the assessment of NPC outcomes. VAC-010 participants who did not receive both vaccinations were excluded.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="94"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 (Week 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="90"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="94"/>
                    <count group_id="O4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="86"/>
                    <measurement group_id="O4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (Week 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="90"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="94"/>
                    <count group_id="O4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="80"/>
                    <measurement group_id="O4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (Week 16)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="91"/>
                    <count group_id="O4" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="81"/>
                    <measurement group_id="O4" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Week 20)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="90"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="88"/>
                    <count group_id="O4" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="81"/>
                    <measurement group_id="O4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (Week 32)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="89"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="83"/>
                    <count group_id="O4" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="71"/>
                    <measurement group_id="O4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Density of Streptococcus Pneumoniae in the Nasopharynx</title>
        <description>The density of Streptococcus pneumoniae (SPn) in the nasopharynx was measured by the number of autolysin (LytA) gene copies detected by quantitative polymerase chain reaction (qPCR) from nasopharyngeal swabs taken at each study visit.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
        <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
        <population>The Nasopharyngeal Carriage (NPC) population with available LytA data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Combined PATH–wSP 300 µg</title>
            <description>All participants who received PATH–wSP 300 µg, including participants in the PATH-wSP 300 µg + Booster and participants in the PATH-wSP 300 µg Only treatment groups.</description>
          </group>
          <group group_id="O2">
            <title>Combined Control (300 µg)</title>
            <description>Participants enrolled during Cohort 1 who received booster-only or no intervention.</description>
          </group>
          <group group_id="O3">
            <title>Combined PATH-wSP 600 µg</title>
            <description>All participants who received PATH–wSP 600 µg, including participants in the PATH-wSP 600 µg + Booster and participants in the PATH-wSP 600 µg Only treatment groups.</description>
          </group>
          <group group_id="O4">
            <title>Combined Control (600 µg)</title>
            <description>All participants enrolled during Cohort 2 who received booster-only or no intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Density of Streptococcus Pneumoniae in the Nasopharynx</title>
          <description>The density of Streptococcus pneumoniae (SPn) in the nasopharynx was measured by the number of autolysin (LytA) gene copies detected by quantitative polymerase chain reaction (qPCR) from nasopharyngeal swabs taken at each study visit.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
          <population>The Nasopharyngeal Carriage (NPC) population with available LytA data at each time point</population>
          <units>log LytA copies</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 (Week 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" lower_limit="12.4" upper_limit="14.6"/>
                    <measurement group_id="O2" value="12.5" lower_limit="11.7" upper_limit="14.4"/>
                    <measurement group_id="O3" value="13.9" lower_limit="13.2" upper_limit="14.5"/>
                    <measurement group_id="O4" value="13.8" lower_limit="12.9" upper_limit="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (Week 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" lower_limit="12.9" upper_limit="14.9"/>
                    <measurement group_id="O2" value="13.0" lower_limit="11.3" upper_limit="14.3"/>
                    <measurement group_id="O3" value="16.4" lower_limit="15.6" upper_limit="17.2"/>
                    <measurement group_id="O4" value="15.9" lower_limit="14.7" upper_limit="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (Week 16)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7" lower_limit="14.0" upper_limit="15.2"/>
                    <measurement group_id="O2" value="14.5" lower_limit="13.6" upper_limit="15.7"/>
                    <measurement group_id="O3" value="16.8" lower_limit="16.0" upper_limit="17.3"/>
                    <measurement group_id="O4" value="16.5" lower_limit="15.2" upper_limit="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Week 20)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1" lower_limit="14.4" upper_limit="15.8"/>
                    <measurement group_id="O2" value="14.0" lower_limit="13.1" upper_limit="15.2"/>
                    <measurement group_id="O3" value="15.5" lower_limit="14.6" upper_limit="16.3"/>
                    <measurement group_id="O4" value="15.1" lower_limit="14.1" upper_limit="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (Week 32)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="65"/>
                    <count group_id="O4" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8" lower_limit="16.2" upper_limit="17.3"/>
                    <measurement group_id="O2" value="14.9" lower_limit="14.5" upper_limit="16.0"/>
                    <measurement group_id="O3" value="14.9" lower_limit="14.1" upper_limit="15.7"/>
                    <measurement group_id="O4" value="14.8" lower_limit="14.0" upper_limit="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentration (GMC) of Immunoglobulin G (IgG) Antibodies Against Pneumococcal Proteins</title>
        <description>Immunogenicity was evaluated based on the following assays:
Immunoglobulin (IgG) response to pneumolysoid [L460D] and pneumococcal surface protein A family 1 [PspA-Fam1] was measured by enzyme-linked immunosorbent assay (ELISA).
IgG response to the following pneumococcal proteins was measured using the Meso Scale Discovery (MSD) platform:
L460D
PspA-Fam1
Pneumococcal histidine triad D (PhtD)
Boston Children's Hospital protein 785 (BCH0785)
Serine threonine kinase protein (StkP)
Pneumococcal choline-binding protein A (PcpA)
Streptococcus pneumonia whole cell antigen (SPWCA)
Pneumococcal iron uptake protein A (PiuA)
Pneumococcal iron acquisition protein A (PiaA)</description>
        <time_frame>Baseline (Week 0), 4 weeks post-vaccination 2 (Week 12), and 6 months post-vaccination 2 (Week 32).</time_frame>
        <population>The Immunogenicity (IG) population includes participants enrolled in Study VAC-010 with at least one usable value in the VAC-011 immunogenicity data set. VAC-010 participants who did not receive both vaccinations were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>PATH-wSP 300 µg + Booster</title>
            <description>Toddlers who enrolled in Cohort 1 of Study VAC-010 and received 300 µg PATH-wSP plus the two booster vaccines (Synflorix and Pentavac) followed by a 2nd injection of 300 µg PATH-wSP 8 weeks later.</description>
          </group>
          <group group_id="O2">
            <title>PATH-wSP 300 µg Only</title>
            <description>Toddlers who enrolled in Cohort 1 of Study VAC-010 and received 300 µg PATH-wSP and 2 saline injections followed by a 2nd injection of 300 µg PATH-wSP 8 weeks later.</description>
          </group>
          <group group_id="O3">
            <title>PATH-wSP 600 µg + Booster</title>
            <description>Toddlers who enrolled in Cohort 2 of Study VAC-010 and received 600 µg PATH-wSP plus the two booster vaccines (Synflorix and Pentavac) followed by a 2nd injection of 600 µg PATH-wSP 8 weeks later.</description>
          </group>
          <group group_id="O4">
            <title>PATH-wSP 600 µg Only</title>
            <description>Toddlers who enrolled in Cohort 2 of Study VAC-010 and received 600 µg PATH-wSP and 2 saline injections followed by a 2nd injection of 600 µg PATH-wSP 8 weeks later.</description>
          </group>
          <group group_id="O5">
            <title>Booster Only (Both Cohorts)</title>
            <description>Toddlers who enrolled in Cohort 1 or Cohort 2 of Study VAC-010 and received one saline injection and the two booster vaccines (Synflorix and Pentavac) followed by a 2nd saline injection 8 weeks later.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) of Immunoglobulin G (IgG) Antibodies Against Pneumococcal Proteins</title>
          <description>Immunogenicity was evaluated based on the following assays:
Immunoglobulin (IgG) response to pneumolysoid [L460D] and pneumococcal surface protein A family 1 [PspA-Fam1] was measured by enzyme-linked immunosorbent assay (ELISA).
IgG response to the following pneumococcal proteins was measured using the Meso Scale Discovery (MSD) platform:
L460D
PspA-Fam1
Pneumococcal histidine triad D (PhtD)
Boston Children's Hospital protein 785 (BCH0785)
Serine threonine kinase protein (StkP)
Pneumococcal choline-binding protein A (PcpA)
Streptococcus pneumonia whole cell antigen (SPWCA)
Pneumococcal iron uptake protein A (PiuA)
Pneumococcal iron acquisition protein A (PiaA)</description>
          <population>The Immunogenicity (IG) population includes participants enrolled in Study VAC-010 with at least one usable value in the VAC-011 immunogenicity data set. VAC-010 participants who did not receive both vaccinations were excluded.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pneumolysoid (L460D): Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="381.12" lower_limit="272.73" upper_limit="532.58"/>
                    <measurement group_id="O2" value="330.58" lower_limit="218.99" upper_limit="499.03"/>
                    <measurement group_id="O3" value="785.54" lower_limit="546.78" upper_limit="1128.56"/>
                    <measurement group_id="O4" value="832.32" lower_limit="561.77" upper_limit="1233.19"/>
                    <measurement group_id="O5" value="497.88" lower_limit="329.88" upper_limit="751.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumolysoid (L460D): 4 weeks post-Vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="813.00" lower_limit="560.96" upper_limit="1178.29"/>
                    <measurement group_id="O2" value="786.26" lower_limit="539.05" upper_limit="1146.83"/>
                    <measurement group_id="O3" value="1600" lower_limit="1130.57" upper_limit="2264.35"/>
                    <measurement group_id="O4" value="2330.97" lower_limit="1571" upper_limit="3457.66"/>
                    <measurement group_id="O5" value="545.42" lower_limit="377.42" upper_limit="788.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumolysoid (L460D): 6 months post-Vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1069.31" lower_limit="739.69" upper_limit="1545.80"/>
                    <measurement group_id="O2" value="1212.57" lower_limit="894.84" upper_limit="1643.12"/>
                    <measurement group_id="O3" value="1372.33" lower_limit="1021.16" upper_limit="1844.25"/>
                    <measurement group_id="O4" value="1697.94" lower_limit="1224.11" upper_limit="2355.18"/>
                    <measurement group_id="O5" value="1051.76" lower_limit="757.13" upper_limit="1461.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PspA-Fam1 (ELISA): Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="397.94" lower_limit="284.00" upper_limit="557.59"/>
                    <measurement group_id="O2" value="382.99" lower_limit="277.26" upper_limit="529.05"/>
                    <measurement group_id="O3" value="602.57" lower_limit="450.01" upper_limit="806.85"/>
                    <measurement group_id="O4" value="725.31" lower_limit="533.27" upper_limit="986.52"/>
                    <measurement group_id="O5" value="513.79" lower_limit="388.35" upper_limit="679.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PspA-Fam1 (ELISA): 4 weeks post-Vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="720.33" lower_limit="551.98" upper_limit="940.03"/>
                    <measurement group_id="O2" value="571.29" lower_limit="418.14" upper_limit="780.55"/>
                    <measurement group_id="O3" value="870.53" lower_limit="672.36" upper_limit="1127.10"/>
                    <measurement group_id="O4" value="1409.82" lower_limit="979.31" upper_limit="2029.60"/>
                    <measurement group_id="O5" value="514.81" lower_limit="362.75" upper_limit="730.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PspA-Fam1 (ELISA): 6 months post-Vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="873.74" lower_limit="618.19" upper_limit="1234.94"/>
                    <measurement group_id="O2" value="824.96" lower_limit="558.84" upper_limit="1217.81"/>
                    <measurement group_id="O3" value="762.72" lower_limit="555.97" upper_limit="1046.35"/>
                    <measurement group_id="O4" value="1239.01" lower_limit="892.62" upper_limit="1719.83"/>
                    <measurement group_id="O5" value="796.22" lower_limit="557.37" upper_limit="1137.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>L460D: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="261.25" lower_limit="199.66" upper_limit="341.84"/>
                    <measurement group_id="O2" value="234.51" lower_limit="171.83" upper_limit="320.05"/>
                    <measurement group_id="O3" value="314.86" lower_limit="240.39" upper_limit="412.41"/>
                    <measurement group_id="O4" value="346.26" lower_limit="273.01" upper_limit="439.16"/>
                    <measurement group_id="O5" value="241.08" lower_limit="187.27" upper_limit="310.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>L460D: 4 weeks post-Vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="460.91" lower_limit="344.59" upper_limit="616.50"/>
                    <measurement group_id="O2" value="440.19" lower_limit="335.66" upper_limit="577.28"/>
                    <measurement group_id="O3" value="622.67" lower_limit="484.23" upper_limit="800.70"/>
                    <measurement group_id="O4" value="917.86" lower_limit="696.84" upper_limit="1208.97"/>
                    <measurement group_id="O5" value="303.90" lower_limit="234.88" upper_limit="393.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>L460D: 6 months post-Vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="499.10" lower_limit="373.82" upper_limit="666.36"/>
                    <measurement group_id="O2" value="525.38" lower_limit="413.09" upper_limit="668.18"/>
                    <measurement group_id="O3" value="508.30" lower_limit="384.86" upper_limit="671.33"/>
                    <measurement group_id="O4" value="701.06" lower_limit="551.11" upper_limit="891.80"/>
                    <measurement group_id="O5" value="380.59" lower_limit="294.18" upper_limit="492.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PspA-Fam1 (MSD): Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172.25" lower_limit="116.10" upper_limit="255.57"/>
                    <measurement group_id="O2" value="195.25" lower_limit="128.65" upper_limit="296.33"/>
                    <measurement group_id="O3" value="219.55" lower_limit="151.45" upper_limit="318.27"/>
                    <measurement group_id="O4" value="231.28" lower_limit="156.45" upper_limit="341.90"/>
                    <measurement group_id="O5" value="218.24" lower_limit="153.16" upper_limit="310.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PspA-Fam1 (MSD): 4 weeks post-Vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="368.08" lower_limit="261.00" upper_limit="519.08"/>
                    <measurement group_id="O2" value="357.83" lower_limit="242.60" upper_limit="527.79"/>
                    <measurement group_id="O3" value="349.00" lower_limit="254.08" upper_limit="479.38"/>
                    <measurement group_id="O4" value="609.24" lower_limit="406.57" upper_limit="912.93"/>
                    <measurement group_id="O5" value="213.82" lower_limit="137.75" upper_limit="331.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PspA-Fam1 (MSD): 6 months post-Vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="303.31" lower_limit="208.18" upper_limit="441.91"/>
                    <measurement group_id="O2" value="339.07" lower_limit="220.62" upper_limit="521.10"/>
                    <measurement group_id="O3" value="362.35" lower_limit="264.93" upper_limit="495.58"/>
                    <measurement group_id="O4" value="548.93" lower_limit="383.92" upper_limit="784.84"/>
                    <measurement group_id="O5" value="317.09" lower_limit="213.51" upper_limit="470.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PhtD: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="464.43" lower_limit="335.55" upper_limit="642.80"/>
                    <measurement group_id="O2" value="456.19" lower_limit="339.35" upper_limit="613.26"/>
                    <measurement group_id="O3" value="464.52" lower_limit="315.74" upper_limit="683.42"/>
                    <measurement group_id="O4" value="555.72" lower_limit="415.87" upper_limit="742.60"/>
                    <measurement group_id="O5" value="377.18" lower_limit="272.45" upper_limit="522.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PhtD: 4 weeks post-Vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="847.28" lower_limit="636.32" upper_limit="1128.18"/>
                    <measurement group_id="O2" value="773.24" lower_limit="610.73" upper_limit="979.01"/>
                    <measurement group_id="O3" value="702.42" lower_limit="512.66" upper_limit="962.40"/>
                    <measurement group_id="O4" value="1174.38" lower_limit="910.85" upper_limit="1514.14"/>
                    <measurement group_id="O5" value="575.56" lower_limit="423.05" upper_limit="783.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PhtD: 6 months post-Vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1128.66" lower_limit="851.33" upper_limit="1496.33"/>
                    <measurement group_id="O2" value="1163.21" lower_limit="946.47" upper_limit="1429.57"/>
                    <measurement group_id="O3" value="926.31" lower_limit="692.19" upper_limit="1239.60"/>
                    <measurement group_id="O4" value="1282.89" lower_limit="975.69" upper_limit="1686.81"/>
                    <measurement group_id="O5" value="890.03" lower_limit="659.09" upper_limit="1201.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCH0785: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="401.04" lower_limit="289.77" upper_limit="555.05"/>
                    <measurement group_id="O2" value="322.75" lower_limit="239.06" upper_limit="435.74"/>
                    <measurement group_id="O3" value="267.80" lower_limit="187.61" upper_limit="382.28"/>
                    <measurement group_id="O4" value="371.19" lower_limit="258.34" upper_limit="533.31"/>
                    <measurement group_id="O5" value="314.85" lower_limit="213.23" upper_limit="464.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCH0785: 4 weeks post-Vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="555.25" lower_limit="396.67" upper_limit="777.24"/>
                    <measurement group_id="O2" value="514.90" lower_limit="400.37" upper_limit="662.18"/>
                    <measurement group_id="O3" value="411.22" lower_limit="297.25" upper_limit="568.88"/>
                    <measurement group_id="O4" value="761.38" lower_limit="541.86" upper_limit="1069.83"/>
                    <measurement group_id="O5" value="397.66" lower_limit="280.80" upper_limit="563.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCH0785: 6 months post-Vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="539.24" lower_limit="406.71" upper_limit="714.95"/>
                    <measurement group_id="O2" value="602.44" lower_limit="472.33" upper_limit="768.40"/>
                    <measurement group_id="O3" value="385.46" lower_limit="279.12" upper_limit="532.30"/>
                    <measurement group_id="O4" value="726.43" lower_limit="542.87" upper_limit="972.06"/>
                    <measurement group_id="O5" value="460.80" lower_limit="327.57" upper_limit="648.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>StkP: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193.50" lower_limit="135.62" upper_limit="276.08"/>
                    <measurement group_id="O2" value="142.90" lower_limit="107.04" upper_limit="190.79"/>
                    <measurement group_id="O3" value="163.30" lower_limit="110.56" upper_limit="241.20"/>
                    <measurement group_id="O4" value="246.51" lower_limit="170.96" upper_limit="355.45"/>
                    <measurement group_id="O5" value="191.77" lower_limit="136.54" upper_limit="269.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>StkP: 4 weeks post-Vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="334.14" lower_limit="238.90" upper_limit="467.33"/>
                    <measurement group_id="O2" value="240.51" lower_limit="190.85" upper_limit="303.10"/>
                    <measurement group_id="O3" value="253.15" lower_limit="181.99" upper_limit="352.13"/>
                    <measurement group_id="O4" value="444.83" lower_limit="322.88" upper_limit="612.84"/>
                    <measurement group_id="O5" value="235.29" lower_limit="169.75" upper_limit="326.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>StkP: 6 months post-Vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="304.48" lower_limit="219.27" upper_limit="422.80"/>
                    <measurement group_id="O2" value="331.73" lower_limit="262.02" upper_limit="420.00"/>
                    <measurement group_id="O3" value="278.27" lower_limit="197.74" upper_limit="391.60"/>
                    <measurement group_id="O4" value="470.92" lower_limit="345.08" upper_limit="642.66"/>
                    <measurement group_id="O5" value="305.51" lower_limit="214.28" upper_limit="435.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PcpA: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="320.15" lower_limit="199.08" upper_limit="514.86"/>
                    <measurement group_id="O2" value="369.58" lower_limit="213.36" upper_limit="640.18"/>
                    <measurement group_id="O3" value="307.97" lower_limit="160.95" upper_limit="589.28"/>
                    <measurement group_id="O4" value="464.90" lower_limit="278.23" upper_limit="776.80"/>
                    <measurement group_id="O5" value="302.03" lower_limit="177.98" upper_limit="512.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PcpA: 4 weeks post-Vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="383.75" lower_limit="237.14" upper_limit="620.99"/>
                    <measurement group_id="O2" value="358.39" lower_limit="218.41" upper_limit="588.08"/>
                    <measurement group_id="O3" value="387.80" lower_limit="216.85" upper_limit="693.50"/>
                    <measurement group_id="O4" value="527.74" lower_limit="303.33" upper_limit="918.20"/>
                    <measurement group_id="O5" value="351.00" lower_limit="194.02" upper_limit="635.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PcpA: 6 months post-Vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="631.99" lower_limit="394.03" upper_limit="1013.67"/>
                    <measurement group_id="O2" value="681.06" lower_limit="470.01" upper_limit="986.87"/>
                    <measurement group_id="O3" value="633.57" lower_limit="400.16" upper_limit="1003.12"/>
                    <measurement group_id="O4" value="779.77" lower_limit="499.74" upper_limit="1216.72"/>
                    <measurement group_id="O5" value="558.79" lower_limit="338.90" upper_limit="921.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPWCA: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="676.76" lower_limit="584.10" upper_limit="784.10"/>
                    <measurement group_id="O2" value="665.77" lower_limit="575.42" upper_limit="770.30"/>
                    <measurement group_id="O3" value="630.23" lower_limit="527.12" upper_limit="753.50"/>
                    <measurement group_id="O4" value="669.91" lower_limit="590.27" upper_limit="760.29"/>
                    <measurement group_id="O5" value="660.13" lower_limit="575.51" upper_limit="757.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPWCA: 4 weeks post-Vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="852.45" lower_limit="735.87" upper_limit="987.50"/>
                    <measurement group_id="O2" value="782.09" lower_limit="701.14" upper_limit="872.38"/>
                    <measurement group_id="O3" value="815.92" lower_limit="722.01" upper_limit="922.06"/>
                    <measurement group_id="O4" value="965.60" lower_limit="817.61" upper_limit="1140.38"/>
                    <measurement group_id="O5" value="762.31" lower_limit="663.45" upper_limit="875.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPWCA: 6 months post-Vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="849.99" lower_limit="730.32" upper_limit="989.27"/>
                    <measurement group_id="O2" value="908.71" lower_limit="797.98" upper_limit="1034.80"/>
                    <measurement group_id="O3" value="828.46" lower_limit="718.93" upper_limit="954.67"/>
                    <measurement group_id="O4" value="1020.25" lower_limit="895.70" upper_limit="1162.12"/>
                    <measurement group_id="O5" value="700.71" lower_limit="595.24" upper_limit="824.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PiuA: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="685.69" lower_limit="530.35" upper_limit="886.53"/>
                    <measurement group_id="O2" value="631.45" lower_limit="489.14" upper_limit="815.17"/>
                    <measurement group_id="O3" value="585.28" lower_limit="451.15" upper_limit="759.30"/>
                    <measurement group_id="O4" value="697.84" lower_limit="521.35" upper_limit="934.08"/>
                    <measurement group_id="O5" value="608.91" lower_limit="457.96" upper_limit="809.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PiuA: 4 weeks post-Vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="938.09" lower_limit="717.50" upper_limit="1226.49"/>
                    <measurement group_id="O2" value="867.54" lower_limit="693.68" upper_limit="1084.98"/>
                    <measurement group_id="O3" value="925.23" lower_limit="758.38" upper_limit="1128.79"/>
                    <measurement group_id="O4" value="1164.80" lower_limit="894.83" upper_limit="1516.20"/>
                    <measurement group_id="O5" value="743.11" lower_limit="574.02" upper_limit="962.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PiuA: 6 months post-Vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1035.89" lower_limit="806.39" upper_limit="1330.70"/>
                    <measurement group_id="O2" value="1274.26" lower_limit="989.51" upper_limit="1640.94"/>
                    <measurement group_id="O3" value="998.07" lower_limit="795.24" upper_limit="1252.64"/>
                    <measurement group_id="O4" value="1188.92" lower_limit="927.29" upper_limit="1524.37"/>
                    <measurement group_id="O5" value="923.97" lower_limit="665.80" upper_limit="1282.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PiaA: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="650.37" lower_limit="494.57" upper_limit="855.26"/>
                    <measurement group_id="O2" value="560.35" lower_limit="406.33" upper_limit="772.74"/>
                    <measurement group_id="O3" value="604.16" lower_limit="453.70" upper_limit="804.50"/>
                    <measurement group_id="O4" value="886.79" lower_limit="678.57" upper_limit="1158.92"/>
                    <measurement group_id="O5" value="606.15" lower_limit="472.84" upper_limit="777.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PiaA: 4 weeks post-Vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="930.90" lower_limit="705.04" upper_limit="1229.10"/>
                    <measurement group_id="O2" value="851.40" lower_limit="651.29" upper_limit="1113.01"/>
                    <measurement group_id="O3" value="788.37" lower_limit="626.08" upper_limit="992.72"/>
                    <measurement group_id="O4" value="1574.97" lower_limit="1207.40" upper_limit="2054.43"/>
                    <measurement group_id="O5" value="805.26" lower_limit="605.90" upper_limit="1070.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PiaA: 6 months post-Vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1014.92" lower_limit="782.79" upper_limit="1315.88"/>
                    <measurement group_id="O2" value="1055.71" lower_limit="782.89" upper_limit="1423.60"/>
                    <measurement group_id="O3" value="732.05" lower_limit="556.80" upper_limit="962.48"/>
                    <measurement group_id="O4" value="1428.92" lower_limit="1120.44" upper_limit="1822.33"/>
                    <measurement group_id="O5" value="816.56" lower_limit="605.56" upper_limit="1101.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentration Ratios of Immunoglobulin G (IgG) Antibodies Against Pneumococcal Proteins for PATH-wSP Groups Versus the Booster Only Group</title>
        <description>Data reported are the geometric mean concentration at 6 months post-vaccination 2 (Week 32) for each PATH-wSP group divided by the Booster (Synflorix and Pentavax)-only group (N=38). Immunogenicity was evaluated based on the following assays:
Immunoglobulin (IgG) response to pneumolysoid (L460D) and pneumococcal surface protein A family 1 (PspA-Fam1) was measured by enzyme-linked immunosorbent assay (ELISA).
IgG response to the following pneumococcal proteins was measured using the Meso Scale Discovery (MSD) platform:
L460D
PspA-Fam1
Pneumococcal histidine triad D (PhtD)
Boston Children's Hospital protein 785 (BCH0785)
Serine threonine kinase protein (StkP)
Pneumococcal choline-binding protein A (PcpA)
Streptococcus pneumonia whole cell antigen (SPWCA)
Pneumococcal iron uptake protein A (PiuA)
Pneumococcal iron acquisition protein A (PiaA)</description>
        <time_frame>Week 32</time_frame>
        <population>Immunogenicity population</population>
        <group_list>
          <group group_id="O1">
            <title>PATH-wSP 300 µg + Booster</title>
            <description>Toddlers who enrolled in Cohort 1 of Study VAC-010 and received 300 µg PATH-wSP plus the two booster vaccines (Synflorix and Pentavac) followed by a 2nd injection of 300 µg PATH-wSP 8 weeks later.</description>
          </group>
          <group group_id="O2">
            <title>PATH-wSP 300 µg Only</title>
            <description>Toddlers who enrolled in Cohort 1 of Study VAC-010 and received 300 µg PATH-wSP and 2 saline injections followed by a 2nd injection of 300 µg PATH-wSP 8 weeks later.</description>
          </group>
          <group group_id="O3">
            <title>PATH-wSP 600 µg + Booster</title>
            <description>Toddlers who enrolled in Cohort 2 of Study VAC-010 and received 600 µg PATH-wSP plus the two booster vaccines (Synflorix and Pentavac) followed by a 2nd injection of 600 µg PATH-wSP 8 weeks later.</description>
          </group>
          <group group_id="O4">
            <title>PATH-wSP 600 µg Only</title>
            <description>Toddlers who enrolled in Cohort 2 of Study VAC-010 and received 600 µg PATH-wSP and 2 saline injections followed by a 2nd injection of 600 µg PATH-wSP 8 weeks later.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration Ratios of Immunoglobulin G (IgG) Antibodies Against Pneumococcal Proteins for PATH-wSP Groups Versus the Booster Only Group</title>
          <description>Data reported are the geometric mean concentration at 6 months post-vaccination 2 (Week 32) for each PATH-wSP group divided by the Booster (Synflorix and Pentavax)-only group (N=38). Immunogenicity was evaluated based on the following assays:
Immunoglobulin (IgG) response to pneumolysoid (L460D) and pneumococcal surface protein A family 1 (PspA-Fam1) was measured by enzyme-linked immunosorbent assay (ELISA).
IgG response to the following pneumococcal proteins was measured using the Meso Scale Discovery (MSD) platform:
L460D
PspA-Fam1
Pneumococcal histidine triad D (PhtD)
Boston Children's Hospital protein 785 (BCH0785)
Serine threonine kinase protein (StkP)
Pneumococcal choline-binding protein A (PcpA)
Streptococcus pneumonia whole cell antigen (SPWCA)
Pneumococcal iron uptake protein A (PiuA)
Pneumococcal iron acquisition protein A (PiaA)</description>
          <population>Immunogenicity population</population>
          <units>ratio</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pneumolysoid (L460D)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" lower_limit="0.62" upper_limit="1.67"/>
                    <measurement group_id="O2" value="1.15" lower_limit="0.74" upper_limit="1.79"/>
                    <measurement group_id="O3" value="1.30" lower_limit="0.84" upper_limit="2.02"/>
                    <measurement group_id="O4" value="1.61" lower_limit="1.02" upper_limit="2.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PspA-Fam1 (ELISA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" lower_limit="0.67" upper_limit="1.79"/>
                    <measurement group_id="O2" value="1.04" lower_limit="0.61" upper_limit="1.75"/>
                    <measurement group_id="O3" value="0.96" lower_limit="0.60" upper_limit="1.53"/>
                    <measurement group_id="O4" value="1.56" lower_limit="0.96" upper_limit="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>L460D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" lower_limit="0.89" upper_limit="1.93"/>
                    <measurement group_id="O2" value="1.38" lower_limit="0.98" upper_limit="1.95"/>
                    <measurement group_id="O3" value="1.34" lower_limit="0.92" upper_limit="1.94"/>
                    <measurement group_id="O4" value="1.84" lower_limit="1.30" upper_limit="2.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PspA-Fam1 (MSD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" lower_limit="0.56" upper_limit="1.64"/>
                    <measurement group_id="O2" value="1.07" lower_limit="0.60" upper_limit="1.91"/>
                    <measurement group_id="O3" value="1.14" lower_limit="0.69" upper_limit="1.88"/>
                    <measurement group_id="O4" value="1.73" lower_limit="1.02" upper_limit="2.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PhtD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" lower_limit="0.84" upper_limit="1.91"/>
                    <measurement group_id="O2" value="1.31" lower_limit="0.91" upper_limit="1.87"/>
                    <measurement group_id="O3" value="1.04" lower_limit="0.69" upper_limit="1.88"/>
                    <measurement group_id="O4" value="1.44" lower_limit="0.96" upper_limit="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCH0785</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" lower_limit="0.76" upper_limit="1.81"/>
                    <measurement group_id="O2" value="1.31" lower_limit="0.87" upper_limit="1.97"/>
                    <measurement group_id="O3" value="0.84" lower_limit="0.53" upper_limit="1.33"/>
                    <measurement group_id="O4" value="1.58" lower_limit="1.01" upper_limit="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>StkP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.62" upper_limit="1.61"/>
                    <measurement group_id="O2" value="1.09" lower_limit="0.72" upper_limit="1.65"/>
                    <measurement group_id="O3" value="0.91" lower_limit="0.56" upper_limit="1.48"/>
                    <measurement group_id="O4" value="1.54" lower_limit="0.96" upper_limit="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PcpA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" lower_limit="0.57" upper_limit="2.23"/>
                    <measurement group_id="O2" value="1.22" lower_limit="0.66" upper_limit="2.24"/>
                    <measurement group_id="O3" value="1.13" lower_limit="0.58" upper_limit="2.22"/>
                    <measurement group_id="O4" value="1.40" lower_limit="0.72" upper_limit="2.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPWCA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21" lower_limit="0.97" upper_limit="1.51"/>
                    <measurement group_id="O2" value="1.30" lower_limit="1.06" upper_limit="1.59"/>
                    <measurement group_id="O3" value="1.18" lower_limit="0.96" upper_limit="1.46"/>
                    <measurement group_id="O4" value="1.46" lower_limit="1.18" upper_limit="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PiuA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" lower_limit="0.75" upper_limit="1.68"/>
                    <measurement group_id="O2" value="1.38" lower_limit="0.92" upper_limit="2.07"/>
                    <measurement group_id="O3" value="1.08" lower_limit="0.73" upper_limit="1.60"/>
                    <measurement group_id="O4" value="1.29" lower_limit="0.85" upper_limit="1.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PiaA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.24" lower_limit="0.84" upper_limit="1.83"/>
                    <measurement group_id="O2" value="1.29" lower_limit="0.85" upper_limit="1.96"/>
                    <measurement group_id="O3" value="0.90" lower_limit="0.60" upper_limit="1.34"/>
                    <measurement group_id="O4" value="1.75" lower_limit="1.19" upper_limit="2.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Change of Immunoglobulin G (IgG) Antibodies Against Pneumococcal Proteins</title>
        <description>Immunogenicity was evaluated based on the following assays:
IgG response to pneumolysoid [L460D] and pneumococcal surface protein A family 1 [PspA-Fam1] was measured by enzyme-linked immunosorbent assay (ELISA).
IgG response to the following pneumococcal proteins was measured using the Meso Scale Discovery (MSD) platform:
L460D
PspA-Fam1
Pneumococcal histidine triad D (PhtD)
Boston Children's Hospital protein 785 (BCH0785)
Serine threonine kinase protein (StkP)
Pneumococcal choline-binding protein A (PcpA)
Streptococcus pneumonia whole cell antigen (SPWCA)
Pneumococcal iron uptake protein A (PiuA)
Pneumococcal iron acquisition protein A (PiaA)
The fold-change was calculated as the 6-month post-vaccination (Week 32) IgG response divided by the Baseline IgG response.</description>
        <time_frame>Baseline and Week 32</time_frame>
        <population>Immunogenicity Population</population>
        <group_list>
          <group group_id="O1">
            <title>PATH-wSP 300 µg + Booster</title>
            <description>Toddlers who enrolled in Cohort 1 of Study VAC-010 and received 300 µg PATH-wSP plus the two booster vaccines (Synflorix and Pentavac) followed by a 2nd injection of 300 µg PATH-wSP 8 weeks later.</description>
          </group>
          <group group_id="O2">
            <title>PATH-wSP 300 µg Only</title>
            <description>Toddlers who enrolled in Cohort 1 of Study VAC-010 and received 300 µg PATH-wSP and 2 saline injections followed by a 2nd injection of 300 µg PATH-wSP 8 weeks later.</description>
          </group>
          <group group_id="O3">
            <title>PATH-wSP 600 µg + Booster</title>
            <description>Toddlers who enrolled in Cohort 2 of Study VAC-010 and received 600 µg PATH-wSP plus the two booster vaccines (Synflorix and Pentavac) followed by a 2nd injection of 600 µg PATH-wSP 8 weeks later.</description>
          </group>
          <group group_id="O4">
            <title>PATH-wSP 600 µg Only</title>
            <description>Toddlers who enrolled in Cohort 2 of Study VAC-010 and received 600 µg PATH-wSP and 2 saline injections followed by a 2nd injection of 600 µg PATH-wSP 8 weeks later.</description>
          </group>
          <group group_id="O5">
            <title>Booster Only (Both Cohorts)</title>
            <description>Toddlers who enrolled in Cohort 1 or Cohort 2 of Study VAC-010 and received one saline injection and the two booster vaccines (Synflorix and Pentavac) followed by a 2nd saline injection 8 weeks later.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Change of Immunoglobulin G (IgG) Antibodies Against Pneumococcal Proteins</title>
          <description>Immunogenicity was evaluated based on the following assays:
IgG response to pneumolysoid [L460D] and pneumococcal surface protein A family 1 [PspA-Fam1] was measured by enzyme-linked immunosorbent assay (ELISA).
IgG response to the following pneumococcal proteins was measured using the Meso Scale Discovery (MSD) platform:
L460D
PspA-Fam1
Pneumococcal histidine triad D (PhtD)
Boston Children's Hospital protein 785 (BCH0785)
Serine threonine kinase protein (StkP)
Pneumococcal choline-binding protein A (PcpA)
Streptococcus pneumonia whole cell antigen (SPWCA)
Pneumococcal iron uptake protein A (PiuA)
Pneumococcal iron acquisition protein A (PiaA)
The fold-change was calculated as the 6-month post-vaccination (Week 32) IgG response divided by the Baseline IgG response.</description>
          <population>Immunogenicity Population</population>
          <units>fold-change</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pneumolysoid (L460D)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.81" lower_limit="2.09" upper_limit="3.76"/>
                    <measurement group_id="O2" value="3.67" lower_limit="2.88" upper_limit="4.67"/>
                    <measurement group_id="O3" value="1.75" lower_limit="1.36" upper_limit="2.24"/>
                    <measurement group_id="O4" value="2.04" lower_limit="1.54" upper_limit="2.69"/>
                    <measurement group_id="O5" value="2.11" lower_limit="1.47" upper_limit="3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PspA-Fam1 (ELISA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.20" lower_limit="1.64" upper_limit="2.94"/>
                    <measurement group_id="O2" value="2.15" lower_limit="1.50" upper_limit="3.10"/>
                    <measurement group_id="O3" value="1.27" lower_limit="0.89" upper_limit="1.81"/>
                    <measurement group_id="O4" value="1.71" lower_limit="1.20" upper_limit="2.43"/>
                    <measurement group_id="O5" value="1.55" lower_limit="1.15" upper_limit="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>L460D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.91" lower_limit="1.51" upper_limit="2.42"/>
                    <measurement group_id="O2" value="2.24" lower_limit="1.81" upper_limit="2.78"/>
                    <measurement group_id="O3" value="1.61" lower_limit="1.27" upper_limit="2.04"/>
                    <measurement group_id="O4" value="2.02" lower_limit="1.64" upper_limit="2.50"/>
                    <measurement group_id="O5" value="1.58" lower_limit="1.25" upper_limit="1.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PspA-Fam1 (MSD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" lower_limit="1.25" upper_limit="2.49"/>
                    <measurement group_id="O2" value="1.74" lower_limit="1.13" upper_limit="2.66"/>
                    <measurement group_id="O3" value="1.65" lower_limit="1.17" upper_limit="2.32"/>
                    <measurement group_id="O4" value="2.37" lower_limit="1.64" upper_limit="3.44"/>
                    <measurement group_id="O5" value="1.45" lower_limit="1.05" upper_limit="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PhtD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.43" lower_limit="1.87" upper_limit="3.16"/>
                    <measurement group_id="O2" value="2.55" lower_limit="1.96" upper_limit="3.31"/>
                    <measurement group_id="O3" value="1.99" lower_limit="1.48" upper_limit="2.68"/>
                    <measurement group_id="O4" value="2.31" lower_limit="1.81" upper_limit="2.95"/>
                    <measurement group_id="O5" value="2.36" lower_limit="1.77" upper_limit="3.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCH0785</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.34" lower_limit="1.04" upper_limit="1.73"/>
                    <measurement group_id="O2" value="1.87" lower_limit="1.48" upper_limit="2.36"/>
                    <measurement group_id="O3" value="1.44" lower_limit="1.10" upper_limit="1.88"/>
                    <measurement group_id="O4" value="1.96" lower_limit="1.49" upper_limit="2.46"/>
                    <measurement group_id="O5" value="1.59" lower_limit="1.28" upper_limit="1.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>StkP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.57" lower_limit="1.17" upper_limit="2.11"/>
                    <measurement group_id="O2" value="2.32" lower_limit="1.80" upper_limit="2.99"/>
                    <measurement group_id="O3" value="1.70" lower_limit="1.32" upper_limit="2.19"/>
                    <measurement group_id="O4" value="1.91" lower_limit="1.48" upper_limit="2.46"/>
                    <measurement group_id="O5" value="1.59" lower_limit="1.28" upper_limit="1.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PcpA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97" lower_limit="1.44" upper_limit="2.71"/>
                    <measurement group_id="O2" value="1.84" lower_limit="1.16" upper_limit="2.94"/>
                    <measurement group_id="O3" value="2.06" lower_limit="1.36" upper_limit="3.12"/>
                    <measurement group_id="O4" value="1.68" lower_limit="1.19" upper_limit="2.36"/>
                    <measurement group_id="O5" value="1.85" lower_limit="1.19" upper_limit="2.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPWCA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.26" lower_limit="1.04" upper_limit="1.52"/>
                    <measurement group_id="O2" value="1.36" lower_limit="1.17" upper_limit="1.59"/>
                    <measurement group_id="O3" value="1.31" lower_limit="1.11" upper_limit="1.56"/>
                    <measurement group_id="O4" value="1.52" lower_limit="1.35" upper_limit="1.72"/>
                    <measurement group_id="O5" value="1.06" lower_limit="0.88" upper_limit="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PiuA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" lower_limit="1.22" upper_limit="1.88"/>
                    <measurement group_id="O2" value="2.02" lower_limit="1.62" upper_limit="2.51"/>
                    <measurement group_id="O3" value="1.71" lower_limit="1.32" upper_limit="2.20"/>
                    <measurement group_id="O4" value="1.70" lower_limit="1.38" upper_limit="2.10"/>
                    <measurement group_id="O5" value="1.52" lower_limit="1.24" upper_limit="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PiaA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.56" lower_limit="1.18" upper_limit="2.07"/>
                    <measurement group_id="O2" value="1.88" lower_limit="1.39" upper_limit="2.56"/>
                    <measurement group_id="O3" value="1.21" lower_limit="0.99" upper_limit="1.49"/>
                    <measurement group_id="O4" value="1.61" lower_limit="1.23" upper_limit="2.12"/>
                    <measurement group_id="O5" value="1.35" lower_limit="1.03" upper_limit="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Meeting Seroresponse Fold-Rise Categories at 6 Months Post Vaccination 2</title>
        <description>The percentage of participants with a seroresponse, defined as a ≥ 2, ≥ 3, and ≥ 4 fold-rise above Baseline in IgG antibody levels against Pneumococcal proteins. Fold-rise was calculated as the 6-month post-vaccination (Week 32) IgG response divided by the Baseline IgG level.
Immunogenicity was evaluated based on the following assays:
IgG response to pneumolysoid [L460D] and pneumococcal surface protein A family 1 [PspA-Fam1] was measured by enzyme-linked immunosorbent assay (ELISA).
IgG response to the following pneumococcal proteins was measured using the Meso Scale Discovery (MSD) platform:
L460D
PspA-Fam1
Pneumococcal histidine triad D (PhtD)
Boston Children's Hospital protein 785 (BCH0785)
Serine threonine kinase protein (StkP)
Pneumococcal choline-binding protein A (PcpA)
Streptococcus pneumonia whole cell antigen (SPWCA)
Pneumococcal iron uptake protein A (PiuA)
Pneumococcal iron acquisition protein A (PiaA)</description>
        <time_frame>Baseline and Week 32</time_frame>
        <population>Immunogenicity Population</population>
        <group_list>
          <group group_id="O1">
            <title>PATH-wSP 300 µg + Booster</title>
            <description>Toddlers who enrolled in Cohort 1 of Study VAC-010 and received 300 µg PATH-wSP plus the two booster vaccines (Synflorix and Pentavac) followed by a 2nd injection of 300 µg PATH-wSP 8 weeks later.</description>
          </group>
          <group group_id="O2">
            <title>PATH-wSP 300 µg Only</title>
            <description>Toddlers who enrolled in Cohort 1 of Study VAC-010 and received 300 µg PATH-wSP and 2 saline injections followed by a 2nd injection of 300 µg PATH-wSP 8 weeks later.</description>
          </group>
          <group group_id="O3">
            <title>PATH-wSP 600 µg + Booster</title>
            <description>Toddlers who enrolled in Cohort 2 of Study VAC-010 and received 600 µg PATH-wSP plus the two booster vaccines (Synflorix and Pentavac) followed by a 2nd injection of 600 µg PATH-wSP 8 weeks later.</description>
          </group>
          <group group_id="O4">
            <title>PATH-wSP 600 µg Only</title>
            <description>Toddlers who enrolled in Cohort 2 of Study VAC-010 and received 600 µg PATH-wSP and 2 saline injections followed by a 2nd injection of 600 µg PATH-wSP 8 weeks later.</description>
          </group>
          <group group_id="O5">
            <title>Booster Only (Both Cohorts)</title>
            <description>Toddlers who enrolled in Cohort 1 or Cohort 2 of Study VAC-010 and received one saline injection and the two booster vaccines (Synflorix and Pentavac) followed by a 2nd saline injection 8 weeks later.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Meeting Seroresponse Fold-Rise Categories at 6 Months Post Vaccination 2</title>
          <description>The percentage of participants with a seroresponse, defined as a ≥ 2, ≥ 3, and ≥ 4 fold-rise above Baseline in IgG antibody levels against Pneumococcal proteins. Fold-rise was calculated as the 6-month post-vaccination (Week 32) IgG response divided by the Baseline IgG level.
Immunogenicity was evaluated based on the following assays:
IgG response to pneumolysoid [L460D] and pneumococcal surface protein A family 1 [PspA-Fam1] was measured by enzyme-linked immunosorbent assay (ELISA).
IgG response to the following pneumococcal proteins was measured using the Meso Scale Discovery (MSD) platform:
L460D
PspA-Fam1
Pneumococcal histidine triad D (PhtD)
Boston Children's Hospital protein 785 (BCH0785)
Serine threonine kinase protein (StkP)
Pneumococcal choline-binding protein A (PcpA)
Streptococcus pneumonia whole cell antigen (SPWCA)
Pneumococcal iron uptake protein A (PiuA)
Pneumococcal iron acquisition protein A (PiaA)</description>
          <population>Immunogenicity Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pneumolysoid (L460D): ≥ 2 Fold-Rise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.1" lower_limit="58.74" upper_limit="83.04"/>
                    <measurement group_id="O2" value="87.5" lower_limit="75.50" upper_limit="94.94"/>
                    <measurement group_id="O3" value="60.5" lower_limit="45.90" upper_limit="73.86"/>
                    <measurement group_id="O4" value="62.9" lower_limit="47.56" upper_limit="76.44"/>
                    <measurement group_id="O5" value="55.3" lower_limit="40.75" upper_limit="69.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumolysoid (L460D): ≥ 3 Fold-Rise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.2" lower_limit="31.20" upper_limit="57.80"/>
                    <measurement group_id="O2" value="57.5" lower_limit="43.31" upper_limit="70.82"/>
                    <measurement group_id="O3" value="28.9" lower_limit="17.16" upper_limit="43.33"/>
                    <measurement group_id="O4" value="34.3" lower_limit="21.12" upper_limit="49.55"/>
                    <measurement group_id="O5" value="39.5" lower_limit="26.14" upper_limit="54.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumolysoid (L460D): ≥4 Fold-Rise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.2" lower_limit="31.20" upper_limit="57.80"/>
                    <measurement group_id="O2" value="57.5" lower_limit="43.31" upper_limit="70.82"/>
                    <measurement group_id="O3" value="26.3" lower_limit="15.03" upper_limit="40.54"/>
                    <measurement group_id="O4" value="34.3" lower_limit="21.12" upper_limit="49.55"/>
                    <measurement group_id="O5" value="39.5" lower_limit="26.14" upper_limit="54.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PspA-Fam1 (ELISA): ≥ 2 Fold-Rise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.9" lower_limit="29.08" upper_limit="55.52"/>
                    <measurement group_id="O2" value="60.0" lower_limit="45.78" upper_limit="73.06"/>
                    <measurement group_id="O3" value="28.9" lower_limit="17.16" upper_limit="43.33"/>
                    <measurement group_id="O4" value="42.9" lower_limit="28.58" upper_limit="58.08"/>
                    <measurement group_id="O5" value="36.8" lower_limit="23.83" upper_limit="51.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PspA-Fam1 (ELISA): ≥ 3 Fold-Rise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.6" lower_limit="20.88" upper_limit="46.13"/>
                    <measurement group_id="O2" value="42.5" lower_limit="29.18" upper_limit="56.69"/>
                    <measurement group_id="O3" value="15.8" lower_limit="7.11" upper_limit="28.80"/>
                    <measurement group_id="O4" value="37.1" lower_limit="23.56" upper_limit="52.44"/>
                    <measurement group_id="O5" value="26.3" lower_limit="15.03" upper_limit="40.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PspA-Fam1 (ELISA): ≥ 4 Fold-Rise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6" lower_limit="15.06" upper_limit="38.77"/>
                    <measurement group_id="O2" value="30.0" lower_limit="18.31" upper_limit="44.03"/>
                    <measurement group_id="O3" value="13.2" lower_limit="5.33" upper_limit="25.70"/>
                    <measurement group_id="O4" value="22.9" lower_limit="11.91" upper_limit="37.48"/>
                    <measurement group_id="O5" value="23.7" lower_limit="12.95" upper_limit="37.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>L460D: ≥ 2 Fold-Rise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.5" lower_limit="33.35" upper_limit="60.05"/>
                    <measurement group_id="O2" value="52.5" lower_limit="38.48" upper_limit="66.23"/>
                    <measurement group_id="O3" value="34.2" lower_limit="21.56" upper_limit="48.80"/>
                    <measurement group_id="O4" value="48.6" lower_limit="33.79" upper_limit="63.54"/>
                    <measurement group_id="O5" value="36.8" lower_limit="23.83" upper_limit="51.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>L460D: ≥ 3 Fold-Rise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3" lower_limit="13.20" upper_limit="36.25"/>
                    <measurement group_id="O2" value="40.0" lower_limit="26.94" upper_limit="54.22"/>
                    <measurement group_id="O3" value="15.8" lower_limit="7.11" upper_limit="28.80"/>
                    <measurement group_id="O4" value="31.4" lower_limit="18.73" upper_limit="46.61"/>
                    <measurement group_id="O5" value="18.4" lower_limit="8.98" upper_limit="31.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>L460D: ≥ 4 Fold-Rise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" lower_limit="6.26" upper_limit="25.69"/>
                    <measurement group_id="O2" value="27.5" lower_limit="16.25" upper_limit="41.39"/>
                    <measurement group_id="O3" value="10.5" lower_limit="3.68" upper_limit="22.49"/>
                    <measurement group_id="O4" value="17.1" lower_limit="7.74" upper_limit="31.06"/>
                    <measurement group_id="O5" value="10.5" lower_limit="3.68" upper_limit="22.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PspA-Fam1 (MSD): ≥ 2 Fold-Rise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.6" lower_limit="20.88" upper_limit="46.13"/>
                    <measurement group_id="O2" value="37.5" lower_limit="24.73" upper_limit="51.72"/>
                    <measurement group_id="O3" value="44.7" lower_limit="30.87" upper_limit="59.25"/>
                    <measurement group_id="O4" value="45.7" lower_limit="31.17" upper_limit="60.83"/>
                    <measurement group_id="O5" value="39.5" lower_limit="26.14" upper_limit="54.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PspA-Fam1 (MSD): ≥ 3 Fold-Rise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6" lower_limit="15.06" upper_limit="38.77"/>
                    <measurement group_id="O2" value="30.0" lower_limit="18.31" upper_limit="44.03"/>
                    <measurement group_id="O3" value="31.6" lower_limit="19.34" upper_limit="46.09"/>
                    <measurement group_id="O4" value="42.9" lower_limit="28.58" upper_limit="58.08"/>
                    <measurement group_id="O5" value="21.1" lower_limit="10.93" upper_limit="34.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PspA-Fam1 (MSD): ≥ 4 Fold-Rise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9" lower_limit="11.38" upper_limit="33.68"/>
                    <measurement group_id="O2" value="27.5" lower_limit="16.25" upper_limit="41.39"/>
                    <measurement group_id="O3" value="23.7" lower_limit="12.95" upper_limit="37.69"/>
                    <measurement group_id="O4" value="31.4" lower_limit="18.73" upper_limit="46.61"/>
                    <measurement group_id="O5" value="15.8" lower_limit="7.11" upper_limit="28.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PhtD: ≥ 2 Fold-Ris2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.1" lower_limit="44.48" upper_limit="70.92"/>
                    <measurement group_id="O2" value="50.0" lower_limit="36.11" upper_limit="63.89"/>
                    <measurement group_id="O3" value="57.9" lower_limit="43.31" upper_limit="71.52"/>
                    <measurement group_id="O4" value="54.3" lower_limit="39.17" upper_limit="68.83"/>
                    <measurement group_id="O5" value="60.5" lower_limit="45.90" upper_limit="73.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PhtD: ≥ 3 Fold-Rise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.5" lower_limit="33.35" upper_limit="60.05"/>
                    <measurement group_id="O2" value="40.0" lower_limit="26.94" upper_limit="54.22"/>
                    <measurement group_id="O3" value="28.9" lower_limit="17.16" upper_limit="43.33"/>
                    <measurement group_id="O4" value="40.0" lower_limit="26.05" upper_limit="55.28"/>
                    <measurement group_id="O5" value="42.1" lower_limit="28.48" upper_limit="56.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PhtD: ≥ 4 Fold-Rise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6" lower_limit="15.06" upper_limit="37.77"/>
                    <measurement group_id="O2" value="35.0" lower_limit="22.55" upper_limit="49.49"/>
                    <measurement group_id="O3" value="15.8" lower_limit="7.11" upper_limit="28.80"/>
                    <measurement group_id="O4" value="17.1" lower_limit="7.74" upper_limit="31.06"/>
                    <measurement group_id="O5" value="28.9" lower_limit="17.16" upper_limit="43.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCH0785: ≥ 2 Fold-Rise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.6" lower_limit="20.88" upper_limit="46.13"/>
                    <measurement group_id="O2" value="50.0" lower_limit="36.11" upper_limit="63.89"/>
                    <measurement group_id="O3" value="42.1" lower_limit="28.48" upper_limit="56.69"/>
                    <measurement group_id="O4" value="42.9" lower_limit="28.58" upper_limit="58.08"/>
                    <measurement group_id="O5" value="39.5" lower_limit="26.14" upper_limit="54.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCH0785: ≥ 3 Fold-Rise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3" lower_limit="13.20" upper_limit="36.25"/>
                    <measurement group_id="O2" value="27.5" lower_limit="16.25" upper_limit="41.39"/>
                    <measurement group_id="O3" value="18.4" lower_limit="8.98" upper_limit="31.83"/>
                    <measurement group_id="O4" value="28.6" lower_limit="16.40" upper_limit="43.63"/>
                    <measurement group_id="O5" value="26.3" lower_limit="15.03" upper_limit="40.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCH0785: ≥ 4 Fold-Rise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" lower_limit="6.26" upper_limit="25.69"/>
                    <measurement group_id="O2" value="15.0" lower_limit="6.74" upper_limit="27.47"/>
                    <measurement group_id="O3" value="10.5" lower_limit="3.68" upper_limit="22.49"/>
                    <measurement group_id="O4" value="25.7" lower_limit="14.12" upper_limit="40.58"/>
                    <measurement group_id="O5" value="15.8" lower_limit="7.11" upper_limit="28.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>StkP: ≥ 2 Fold-Rise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.6" lower_limit="20.88" upper_limit="46.13"/>
                    <measurement group_id="O2" value="52.5" lower_limit="38.48" upper_limit="66.23"/>
                    <measurement group_id="O3" value="42.1" lower_limit="28.48" upper_limit="56.69"/>
                    <measurement group_id="O4" value="48.06" lower_limit="33.79" upper_limit="63.54"/>
                    <measurement group_id="O5" value="36.8" lower_limit="23.83" upper_limit="51.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>StkP: ≥ 3 Fold-Rise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9" lower_limit="11.38" upper_limit="33.68"/>
                    <measurement group_id="O2" value="32.5" lower_limit="20.41" upper_limit="46.63"/>
                    <measurement group_id="O3" value="23.7" lower_limit="12.95" upper_limit="37.69"/>
                    <measurement group_id="O4" value="34.3" lower_limit="21.12" upper_limit="49.55"/>
                    <measurement group_id="O5" value="21.1" lower_limit="10.93" upper_limit="34.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>StkP: ≥ 4 Fold-Rise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6" lower_limit="9.61" upper_limit="31.07"/>
                    <measurement group_id="O2" value="27.5" lower_limit="16.25" upper_limit="41.39"/>
                    <measurement group_id="O3" value="10.5" lower_limit="3.68" upper_limit="22.49"/>
                    <measurement group_id="O4" value="20.0" lower_limit="9.78" upper_limit="34.30"/>
                    <measurement group_id="O5" value="13.2" lower_limit="5.33" upper_limit="25.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PcpA: ≥ 2 Fold-Rise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.5" lower_limit="33.35" upper_limit="60.05"/>
                    <measurement group_id="O2" value="42.5" lower_limit="29.18" upper_limit="56.69"/>
                    <measurement group_id="O3" value="50.0" lower_limit="35.74" upper_limit="64.26"/>
                    <measurement group_id="O4" value="40.0" lower_limit="26.05" upper_limit="55.28"/>
                    <measurement group_id="O5" value="39.5" lower_limit="26.14" upper_limit="54.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PcpA: ≥ 3 Fold-Rise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2" lower_limit="18.90" upper_limit="43.71"/>
                    <measurement group_id="O2" value="35.0" lower_limit="22.55" upper_limit="49.19"/>
                    <measurement group_id="O3" value="34.2" lower_limit="21.56" upper_limit="48.80"/>
                    <measurement group_id="O4" value="31.4" lower_limit="18.73" upper_limit="46.61"/>
                    <measurement group_id="O5" value="31.6" lower_limit="19.34" upper_limit="46.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PcpA: ≥ 4 Fold-Rise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6" lower_limit="15.06" upper_limit="38.77"/>
                    <measurement group_id="O2" value="27.5" lower_limit="16.25" upper_limit="41.39"/>
                    <measurement group_id="O3" value="26.3" lower_limit="15.03" upper_limit="40.54"/>
                    <measurement group_id="O4" value="22.9" lower_limit="11.91" upper_limit="37.48"/>
                    <measurement group_id="O5" value="31.6" lower_limit="19.34" upper_limit="46.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPWCA: ≥ 2 Fold-Rise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6" lower_limit="15.06" upper_limit="38.77"/>
                    <measurement group_id="O2" value="22.5" lower_limit="12.27" upper_limit="35.98"/>
                    <measurement group_id="O3" value="26.3" lower_limit="15.03" upper_limit="40.54"/>
                    <measurement group_id="O4" value="31.4" lower_limit="18.73" upper_limit="46.61"/>
                    <measurement group_id="O5" value="21.1" lower_limit="10.93" upper_limit="34.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPWCA: ≥ 3 Fold-Rise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" lower_limit="3.24" upper_limit="20.04"/>
                    <measurement group_id="O2" value="12.5" lower_limit="5.06" upper_limit="24.50"/>
                    <measurement group_id="O3" value="10.5" lower_limit="3.68" upper_limit="22.49"/>
                    <measurement group_id="O4" value="2.9" lower_limit="0.15" upper_limit="12.85"/>
                    <measurement group_id="O5" value="2.6" lower_limit="0.13" upper_limit="11.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPWCA: ≥ 4 Fold-Rise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" lower_limit="0.83" upper_limit="13.93"/>
                    <measurement group_id="O2" value="7.5" lower_limit="2.08" upper_limit="18.26"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.00" upper_limit="7.58"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="8.20"/>
                    <measurement group_id="O5" value="2.6" lower_limit="0.13" upper_limit="11.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PiuA: ≥ 2 Fold-Rise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.6" lower_limit="20.88" upper_limit="46.13"/>
                    <measurement group_id="O2" value="52.5" lower_limit="38.48" upper_limit="66.23"/>
                    <measurement group_id="O3" value="39.5" lower_limit="26.14" upper_limit="54.10"/>
                    <measurement group_id="O4" value="45.7" lower_limit="31.17" upper_limit="60.83"/>
                    <measurement group_id="O5" value="34.2" lower_limit="21.56" upper_limit="48.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PiuA: ≥ 3 Fold-Rise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9" lower_limit="11.38" upper_limit="33.68"/>
                    <measurement group_id="O2" value="27.5" lower_limit="16.25" upper_limit="41.39"/>
                    <measurement group_id="O3" value="26.3" lower_limit="15.03" upper_limit="40.54"/>
                    <measurement group_id="O4" value="22.9" lower_limit="11.91" upper_limit="37.48"/>
                    <measurement group_id="O5" value="13.2" lower_limit="5.33" upper_limit="25.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PiuA: ≥ 4 Fold-Rise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" lower_limit="3.24" upper_limit="20.04"/>
                    <measurement group_id="O2" value="22.5" lower_limit="12.27" upper_limit="35.98"/>
                    <measurement group_id="O3" value="15.8" lower_limit="7.11" upper_limit="28.80"/>
                    <measurement group_id="O4" value="17.1" lower_limit="7.74" upper_limit="31.06"/>
                    <measurement group_id="O5" value="7.9" lower_limit="2.19" upper_limit="19.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PiaA: ≥ 2 Fold-Rise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.9" lower_limit="29.08" upper_limit="55.52"/>
                    <measurement group_id="O2" value="40.0" lower_limit="26.94" upper_limit="54.22"/>
                    <measurement group_id="O3" value="26.3" lower_limit="15.03" upper_limit="40.54"/>
                    <measurement group_id="O4" value="40.0" lower_limit="26.05" upper_limit="55.28"/>
                    <measurement group_id="O5" value="36.8" lower_limit="23.83" upper_limit="51.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PiaA: ≥ 3 Fold-Rise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3" lower_limit="13.20" upper_limit="36.25"/>
                    <measurement group_id="O2" value="25.0" lower_limit="14.24" upper_limit="38.71"/>
                    <measurement group_id="O3" value="7.9" lower_limit="2.19" upper_limit="19.16"/>
                    <measurement group_id="O4" value="20.0" lower_limit="9.78" upper_limit="34.30"/>
                    <measurement group_id="O5" value="21.1" lower_limit="10.93" upper_limit="34.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PiaA: ≥ 4 Fold-Rise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" lower_limit="4.70" upper_limit="22.91"/>
                    <measurement group_id="O2" value="20.0" lower_limit="10.36" upper_limit="33.20"/>
                    <measurement group_id="O3" value="2.6" lower_limit="0.13" upper_limit="11.89"/>
                    <measurement group_id="O4" value="17.1" lower_limit="7.74" upper_limit="31.06"/>
                    <measurement group_id="O5" value="10.5" lower_limit="3.68" upper_limit="22.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Neutralizing Antibody Response to Pneumolysin</title>
        <description>Neutralizing antibody responses to pneumolysin were assessed at Baseline and 6 months post vaccination 2 using an in vitro toxin neutralization assay that measures the ability of antibodies to neutralize wild-type pneumolysin-induced lysis of rabbit red blood cells.
Each sample was categorized as negative (&lt; 1/20 dilution) or positive (with titer between 1/20 and 1/320 dilution). Responses at higher dilutions indicate higher levels of neutralizing antibodies to pneumolysin.</description>
        <time_frame>Baseline (Week 0) and 6 months post-vaccination 2 (Week 32)</time_frame>
        <population>Immunogenicity Population with available neutralizing antibody data.</population>
        <group_list>
          <group group_id="O1">
            <title>PATH-wSP 300 µg + Booster</title>
            <description>Toddlers who enrolled in Cohort 1 of Study VAC-010 and received 300 µg PATH-wSP plus the two booster vaccines (Synflorix and Pentavac) followed by a 2nd injection of 300 µg PATH-wSP 8 weeks later.</description>
          </group>
          <group group_id="O2">
            <title>PATH-wSP 300 µg Only</title>
            <description>Toddlers who enrolled in Cohort 1 of Study VAC-010 and received 300 µg PATH-wSP and 2 saline injections followed by a 2nd injection of 300 µg PATH-wSP 8 weeks later.</description>
          </group>
          <group group_id="O3">
            <title>PATH-wSP 600 µg + Booster</title>
            <description>Toddlers who enrolled in Cohort 2 of Study VAC-010 and received 600 µg PATH-wSP plus the two booster vaccines (Synflorix and Pentavac) followed by a 2nd injection of 600 µg PATH-wSP 8 weeks later.</description>
          </group>
          <group group_id="O4">
            <title>PATH-wSP 600 µg Only</title>
            <description>Toddlers who enrolled in Cohort 2 of Study VAC-010 and received 600 µg PATH-wSP and 2 saline injections followed by a 2nd injection of 600 µg PATH-wSP 8 weeks later.</description>
          </group>
          <group group_id="O5">
            <title>Booster Only (Both Cohorts)</title>
            <description>Toddlers who enrolled in Cohort 1 or Cohort 2 of Study VAC-010 and received one saline injection and the two booster vaccines (Synflorix and Pentavac) followed by a 2nd saline injection 8 weeks later.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Neutralizing Antibody Response to Pneumolysin</title>
          <description>Neutralizing antibody responses to pneumolysin were assessed at Baseline and 6 months post vaccination 2 using an in vitro toxin neutralization assay that measures the ability of antibodies to neutralize wild-type pneumolysin-induced lysis of rabbit red blood cells.
Each sample was categorized as negative (&lt; 1/20 dilution) or positive (with titer between 1/20 and 1/320 dilution). Responses at higher dilutions indicate higher levels of neutralizing antibodies to pneumolysin.</description>
          <population>Immunogenicity Population with available neutralizing antibody data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <title>&lt;1:20 titer</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1:20 titer</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1:40 titer</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1:80 titer</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1:160 titer</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1:320 titer</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months post-vaccination 2</title>
              <category_list>
                <category>
                  <title>&lt;1:20 titer</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1:20 titer</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1:40 titer</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1:80 titer</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1:160 titer</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1:320 titer</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adverse Events (AE)</title>
        <description>An AE was defined as any untoward, undesired, or unplanned event in the form of signs, symptoms, disease, or laboratory or psychological/physiologic observations occurring in a person in a clinical study. The AEs collected in this non-interventional study were those that remained open after the last visit in the VAC-010 Study, those attributed to study vaccine in VAC-010 with onset after the participant exited VAC-010, those that were related to a VAC-011 procedure (i.e. blood draw, nasal swab sample), and all serious adverse events.</description>
        <time_frame>32 weeks; for participants enrolled concurrently in Study VAC-010 adverse events were collected after the last VAC-010 visit through to Week 32.</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>PATH-wSP 300 µg + Booster</title>
            <description>Toddlers who enrolled in Cohort 1 of Study VAC-010 and received 300 µg PATH-wSP plus the two booster vaccines (Synflorix and Pentavac) followed by a 2nd injection of 300 µg PATH-wSP 8 weeks later.</description>
          </group>
          <group group_id="O2">
            <title>PATH-wSP 300 µg Only</title>
            <description>Toddlers who enrolled in Cohort 1 of Study VAC-010 and received 300 µg PATH-wSP and 2 saline injections followed by a 2nd injection of 300 µg PATH-wSP 8 weeks later.</description>
          </group>
          <group group_id="O3">
            <title>PATH-wSP 600 µg + Booster</title>
            <description>Toddlers who enrolled in Cohort 2 of Study VAC-010 and received 600 µg PATH-wSP plus the two booster vaccines (Synflorix and Pentavac) followed by a 2nd injection of 600 µg PATH-wSP 8 weeks later.</description>
          </group>
          <group group_id="O4">
            <title>PATH-wSP 600 µg Only</title>
            <description>Toddlers who enrolled in Cohort 2 of Study VAC-010 and received 600 µg PATH-wSP and 2 saline injections followed by a 2nd injection of 600 µg PATH-wSP 8 weeks later.</description>
          </group>
          <group group_id="O5">
            <title>Booster Only (Both Cohorts)</title>
            <description>Toddlers who enrolled in Cohort 1 or Cohort 2 of Study VAC-010 and received one saline injection and the two booster vaccines (Synflorix and Pentavac) followed by a 2nd saline injection 8 weeks later.</description>
          </group>
          <group group_id="O6">
            <title>No Intervention</title>
            <description>Toddlers who enrolled during Cohort 1 or Cohort 2 who did not participate in Study VAC-010 and did not receive either PATH-wSP or either of the booster vaccines (Pentavac or Synflorix).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events (AE)</title>
          <description>An AE was defined as any untoward, undesired, or unplanned event in the form of signs, symptoms, disease, or laboratory or psychological/physiologic observations occurring in a person in a clinical study. The AEs collected in this non-interventional study were those that remained open after the last visit in the VAC-010 Study, those attributed to study vaccine in VAC-010 with onset after the participant exited VAC-010, those that were related to a VAC-011 procedure (i.e. blood draw, nasal swab sample), and all serious adverse events.</description>
          <population>All enrolled participants</population>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total number of AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious AE: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious AE: Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity: Mild (Grade 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity: Moderate (Grade 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity: Severe (Grade 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity: Potentially Life Threatening (Grade 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity: Death (Grade 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related to vaccine: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related to vaccine: Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prevalence of Streptococcus Pneumoniae Serotype 11A/D/E [11A] in the Nasopharynx</title>
        <description>Nasopharyngeal samples were further analyzed for the prevalence of specific Streptococcus pneumoniae serotypes by microarray. The number of participants with a positive result for SPn serotype 11A/D/E [11A] is reported.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
        <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
        <population>Nasopharyngeal Carriage (NPC) population with culture-confirmed samples and available serotype data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Combined PATH-wSP 300 µg</title>
            <description>All participants who received PATH-wSP 300 µg, including participants in the PATH-wSP 300 µg + Booster and participants in the PATH-wSP 300 µg Only treatment groups.</description>
          </group>
          <group group_id="O2">
            <title>Combined Control (300 µg)</title>
            <description>Participants enrolled during Cohort 1 who received booster-only or no intervention.</description>
          </group>
          <group group_id="O3">
            <title>Combined PATH-wSP 600 µg</title>
            <description>All participants who received PATH-wSP 600 µg, including participants in the PATH-wSP 600 µg + Booster and participants in the PATH-wSP 600 µg Only treatment groups.</description>
          </group>
          <group group_id="O4">
            <title>Combined Control (600 µg)</title>
            <description>All participants enrolled during Cohort 2 who received booster-only or no intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Streptococcus Pneumoniae Serotype 11A/D/E [11A] in the Nasopharynx</title>
          <description>Nasopharyngeal samples were further analyzed for the prevalence of specific Streptococcus pneumoniae serotypes by microarray. The number of participants with a positive result for SPn serotype 11A/D/E [11A] is reported.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
          <population>Nasopharyngeal Carriage (NPC) population with culture-confirmed samples and available serotype data at each time point</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 (Week 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="83"/>
                    <count group_id="O4" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (Week 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="83"/>
                    <count group_id="O4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (Week 16)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Week 20)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (Week 32)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prevalence of Streptococcus Pneumoniae Serotype 13 in the Nasopharynx</title>
        <description>Nasopharyngeal samples were further analyzed for the prevalence of specific Streptococcus pneumoniae serotypes by microarray. The number of participants with a positive result for SPn serotype 13 is reported.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
        <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
        <population>Nasopharyngeal Carriage (NPC) population with culture-confirmed samples and available serotype data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Combined PATH-wSP 300 µg</title>
            <description>All participants who received PATH-wSP 300 µg, including participants in the PATH-wSP 300 µg + Booster and participants in the PATH-wSP 300 µg Only treatment groups.</description>
          </group>
          <group group_id="O2">
            <title>Combined Control (300 µg)</title>
            <description>Participants enrolled during Cohort 1 who received booster-only or no intervention.</description>
          </group>
          <group group_id="O3">
            <title>Combined PATH-wSP 600 µg</title>
            <description>All participants who received PATH-wSP 600 µg, including participants in the PATH-wSP 600 µg + Booster and participants in the PATH-wSP 600 µg Only treatment groups.</description>
          </group>
          <group group_id="O4">
            <title>Combined Control (600 µg)</title>
            <description>All participants enrolled during Cohort 2 who received booster-only or no intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Streptococcus Pneumoniae Serotype 13 in the Nasopharynx</title>
          <description>Nasopharyngeal samples were further analyzed for the prevalence of specific Streptococcus pneumoniae serotypes by microarray. The number of participants with a positive result for SPn serotype 13 is reported.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
          <population>Nasopharyngeal Carriage (NPC) population with culture-confirmed samples and available serotype data at each time point</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 (Week 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="83"/>
                    <count group_id="O4" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (Week 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="83"/>
                    <count group_id="O4" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (Week 16)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Week 20)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (Week 32)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prevalence of Streptococcus Pneumoniae Serotype 15A in the Nasopharynx</title>
        <description>Nasopharyngeal samples were further analyzed for the prevalence of specific Streptococcus pneumoniae serotypes by microarray. The number of participants with a positive result for SPn serotype 15A is reported.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
        <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
        <population>Nasopharyngeal Carriage (NPC) population with culture-confirmed samples and available serotype data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Combined PATH-wSP 300 µg</title>
            <description>All participants who received PATH-wSP 300 µg, including participants in the PATH-wSP 300 µg + Booster and participants in the PATH-wSP 300 µg Only treatment groups.</description>
          </group>
          <group group_id="O2">
            <title>Combined Control (300 µg)</title>
            <description>Participants enrolled during Cohort 1 who received booster-only or no intervention.</description>
          </group>
          <group group_id="O3">
            <title>Combined PATH-wSP 600 µg</title>
            <description>All participants who received PATH-wSP 600 µg, including participants in the PATH-wSP 600 µg + Booster and participants in the PATH-wSP 600 µg Only treatment groups.</description>
          </group>
          <group group_id="O4">
            <title>Combined Control (600 µg)</title>
            <description>All participants enrolled during Cohort 2 who received booster-only or no intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Streptococcus Pneumoniae Serotype 15A in the Nasopharynx</title>
          <description>Nasopharyngeal samples were further analyzed for the prevalence of specific Streptococcus pneumoniae serotypes by microarray. The number of participants with a positive result for SPn serotype 15A is reported.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
          <population>Nasopharyngeal Carriage (NPC) population with culture-confirmed samples and available serotype data at each time point</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 (Week 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="83"/>
                    <count group_id="O4" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (Week 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="83"/>
                    <count group_id="O4" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (Week 16)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Week 20)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (Week 32)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prevalence of Streptococcus Pneumoniae Serotype 15B/C [15B] in the Nasopharynx</title>
        <description>Nasopharyngeal samples were further analyzed for the prevalence of specific Streptococcus pneumoniae serotypes by microarray. The number of participants with a positive result for SPn serotype 15B/C [15B] is reported.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
        <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
        <population>Nasopharyngeal Carriage (NPC) population with culture-confirmed samples and available serotype data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Combined PATH-wSP 300 µg</title>
            <description>All participants who received PATH-wSP 300 µg, including participants in the PATH-wSP 300 µg + Booster and participants in the PATH-wSP 300 µg Only treatment groups.</description>
          </group>
          <group group_id="O2">
            <title>Combined Control (300 µg)</title>
            <description>Participants enrolled during Cohort 1 who received booster-only or no intervention.</description>
          </group>
          <group group_id="O3">
            <title>Combined PATH-wSP 600 µg</title>
            <description>All participants who received PATH-wSP 600 µg, including participants in the PATH-wSP 600 µg + Booster and participants in the PATH-wSP 600 µg Only treatment groups.</description>
          </group>
          <group group_id="O4">
            <title>Combined Control (600 µg)</title>
            <description>All participants enrolled during Cohort 2 who received booster-only or no intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Streptococcus Pneumoniae Serotype 15B/C [15B] in the Nasopharynx</title>
          <description>Nasopharyngeal samples were further analyzed for the prevalence of specific Streptococcus pneumoniae serotypes by microarray. The number of participants with a positive result for SPn serotype 15B/C [15B] is reported.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
          <population>Nasopharyngeal Carriage (NPC) population with culture-confirmed samples and available serotype data at each time point</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 (Week 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="83"/>
                    <count group_id="O4" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (Week 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="84"/>
                    <count group_id="O4" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (Week 16)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Week 20)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (Week 32)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prevalence of Streptococcus Pneumoniae Serotype 19A in the Nasopharynx</title>
        <description>Nasopharyngeal samples were further analyzed for the prevalence of specific Streptococcus pneumoniae serotypes by microarray. The number of participants with a positive result for SPn serotype 19A is reported.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
        <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
        <population>Nasopharyngeal Carriage (NPC) population with culture-confirmed samples and available serotype data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Combined PATH-wSP 300 µg</title>
            <description>All participants who received PATH-wSP 300 µg, including participants in the PATH-wSP 300 µg + Booster and participants in the PATH-wSP 300 µg Only treatment groups.</description>
          </group>
          <group group_id="O2">
            <title>Combined Control (300 µg)</title>
            <description>Participants enrolled during Cohort 1 who received booster-only or no intervention.</description>
          </group>
          <group group_id="O3">
            <title>Combined PATH-wSP 600 µg</title>
            <description>All participants who received PATH-wSP 600 µg, including participants in the PATH-wSP 600 µg + Booster and participants in the PATH-wSP 600 µg Only treatment groups.</description>
          </group>
          <group group_id="O4">
            <title>Combined Control (600 µg)</title>
            <description>All participants enrolled during Cohort 2 who received booster-only or no intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Streptococcus Pneumoniae Serotype 19A in the Nasopharynx</title>
          <description>Nasopharyngeal samples were further analyzed for the prevalence of specific Streptococcus pneumoniae serotypes by microarray. The number of participants with a positive result for SPn serotype 19A is reported.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
          <population>Nasopharyngeal Carriage (NPC) population with culture-confirmed samples and available serotype data at each time point</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 (Week 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="83"/>
                    <count group_id="O4" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (Week 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="84"/>
                    <count group_id="O4" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (Week 16)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Week 20)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (Week 32)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prevalence of Streptococcus Pneumoniae Serotype 19F in the Nasopharynx</title>
        <description>Nasopharyngeal samples were further analyzed for the prevalence of specific Streptococcus pneumoniae serotypes by microarray. The number of participants with a positive result for SPn serotype 19F is reported.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
        <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
        <population>Nasopharyngeal Carriage (NPC) population with culture-confirmed samples and available serotype data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Combined PATH-wSP 300 µg</title>
            <description>All participants who received PATH-wSP 300 µg, including participants in the PATH-wSP 300 µg + Booster and participants in the PATH-wSP 300 µg Only treatment groups.</description>
          </group>
          <group group_id="O2">
            <title>Combined Control (300 µg)</title>
            <description>Participants enrolled during Cohort 1 who received booster-only or no intervention.</description>
          </group>
          <group group_id="O3">
            <title>Combined PATH-wSP 600 µg</title>
            <description>All participants who received PATH-wSP 600 µg, including participants in the PATH-wSP 600 µg + Booster and participants in the PATH-wSP 600 µg Only treatment groups.</description>
          </group>
          <group group_id="O4">
            <title>Combined Control (600 µg)</title>
            <description>All participants enrolled during Cohort 2 who received booster-only or no intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Streptococcus Pneumoniae Serotype 19F in the Nasopharynx</title>
          <description>Nasopharyngeal samples were further analyzed for the prevalence of specific Streptococcus pneumoniae serotypes by microarray. The number of participants with a positive result for SPn serotype 19F is reported.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
          <population>Nasopharyngeal Carriage (NPC) population with culture-confirmed samples and available serotype data at each time point</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 (Week 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="82"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="83"/>
                    <count group_id="O4" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (Week 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="84"/>
                    <count group_id="O4" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (Week 16)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Week 20)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (Week 32)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prevalence of Streptococcus Pneumoniae Serotype 3 in the Nasopharynx</title>
        <description>Nasopharyngeal samples were further analyzed for the prevalence of specific Streptococcus pneumoniae serotypes by microarray. The number of participants with a positive result for SPn serotype 3 is reported.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
        <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
        <population>Nasopharyngeal Carriage (NPC) population with culture-confirmed samples and available serotype data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Combined PATH–wSP 300 µg</title>
            <description>All participants who received PATH-wSP 300 µg, including participants in the PATH-wSP 300 µg + Booster and participants in the PATH-wSP 300 µg Only treatment groups.</description>
          </group>
          <group group_id="O2">
            <title>Combined Control (300 µg)</title>
            <description>Participants enrolled during Cohort 1 who received booster-only or no intervention.</description>
          </group>
          <group group_id="O3">
            <title>Combined PATH-wSP 600 µg</title>
            <description>All participants who received PATH-wSP 600 µg, including participants in the PATH-wSP 600 µg + Booster and participants in the PATH-wSP 600 µg Only treatment groups.</description>
          </group>
          <group group_id="O4">
            <title>Combined Control (600 µg)</title>
            <description>All participants enrolled during Cohort 2 who received booster-only or no intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Streptococcus Pneumoniae Serotype 3 in the Nasopharynx</title>
          <description>Nasopharyngeal samples were further analyzed for the prevalence of specific Streptococcus pneumoniae serotypes by microarray. The number of participants with a positive result for SPn serotype 3 is reported.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
          <population>Nasopharyngeal Carriage (NPC) population with culture-confirmed samples and available serotype data at each time point</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 (Week 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="83"/>
                    <count group_id="O4" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (Week 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="84"/>
                    <count group_id="O4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (Week 16)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Week 20)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (Week 32)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prevalence of Streptococcus Pneumoniae Serotype 35B in the Nasopharynx</title>
        <description>Nasopharyngeal samples were further analyzed for the prevalence of specific Streptococcus pneumoniae serotypes by microarray. The number of participants with a positive result for SPn serotype 35B is reported.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
        <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
        <population>Nasopharyngeal Carriage (NPC) population with culture-confirmed samples and available serotype data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Combined PATH-wSP 300 µg</title>
            <description>All participants who received PATH-wSP 300 µg, including participants in the PATH-wSP 300 µg + Booster and participants in the PATH-wSP 300 µg Only treatment groups.</description>
          </group>
          <group group_id="O2">
            <title>Combined Control (300 µg)</title>
            <description>Participants enrolled during Cohort 1 who received booster-only or no intervention.</description>
          </group>
          <group group_id="O3">
            <title>Combined PATH-wSP 600 µg</title>
            <description>All participants who received PATH-wSP 600 µg, including participants in the PATH-wSP 600 µg + Booster and participants in the PATH-wSP 600 µg Only treatment groups.</description>
          </group>
          <group group_id="O4">
            <title>Combined Control (600 µg)</title>
            <description>All participants enrolled during Cohort 2 who received booster-only or no intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Streptococcus Pneumoniae Serotype 35B in the Nasopharynx</title>
          <description>Nasopharyngeal samples were further analyzed for the prevalence of specific Streptococcus pneumoniae serotypes by microarray. The number of participants with a positive result for SPn serotype 35B is reported.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
          <population>Nasopharyngeal Carriage (NPC) population with culture-confirmed samples and available serotype data at each time point</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 (Week 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="83"/>
                    <count group_id="O4" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (Week 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="84"/>
                    <count group_id="O4" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (Week 16)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Week 20)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (Week 32)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prevalence of Streptococcus Pneumoniae Serotype 6A/B [6A] in the Nasopharynx</title>
        <description>Nasopharyngeal samples were further analyzed for the prevalence of specific Streptococcus pneumoniae serotypes by microarray. The number of participants with a positive result for SPn serotype 6A/B [6A] is reported.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
        <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
        <population>Nasopharyngeal Carriage (NPC) population with culture-confirmed samples and available serotype data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Combined PATH–wSP 300 µg</title>
            <description>All participants who received PATH-wSP 300 µg, including participants in the PATH-wSP 300 µg + Booster and participants in the PATH-wSP 300 µg Only treatment groups.</description>
          </group>
          <group group_id="O2">
            <title>Combined Control (300 µg)</title>
            <description>Participants enrolled during Cohort 1 who received booster-only or no intervention.</description>
          </group>
          <group group_id="O3">
            <title>Combined PATH-wSP 600 µg</title>
            <description>All participants who received PATH-wSP 600 µg, including participants in the PATH-wSP 600 µg + Booster and participants in the PATH-wSP 600 µg Only treatment groups.</description>
          </group>
          <group group_id="O4">
            <title>Combined Control (600 µg)</title>
            <description>All participants enrolled during Cohort 2 who received booster-only or no intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Streptococcus Pneumoniae Serotype 6A/B [6A] in the Nasopharynx</title>
          <description>Nasopharyngeal samples were further analyzed for the prevalence of specific Streptococcus pneumoniae serotypes by microarray. The number of participants with a positive result for SPn serotype 6A/B [6A] is reported.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
          <population>Nasopharyngeal Carriage (NPC) population with culture-confirmed samples and available serotype data at each time point</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 (Week 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="83"/>
                    <count group_id="O4" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (Week 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (Week 16)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Week 20)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (Week 32)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prevalence of Streptococcus Pneumoniae Serotype NT4b in the Nasopharynx</title>
        <description>Nasopharyngeal samples were further analyzed for the prevalence of specific Streptococcus pneumoniae serotypes by microarray. The number of participants with a positive result for SPn serotype NT4b is reported.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
        <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
        <population>Nasopharyngeal Carriage (NPC) population with culture-confirmed samples and available serotype data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Combined PATH-wSP 300 µg</title>
            <description>All participants who received PATH-wSP 300 µg, including participants in the PATH-wSP 300 µg + Booster and participants in the PATH-wSP 300 µg Only treatment groups.</description>
          </group>
          <group group_id="O2">
            <title>Combined Control (300 µg)</title>
            <description>Participants enrolled during Cohort 1 who received booster-only or no intervention.</description>
          </group>
          <group group_id="O3">
            <title>Combined PATH-wSP 600 µg</title>
            <description>All participants who received PATH-wSP 600 µg, including participants in the PATH-wSP 600 µg + Booster and participants in the PATH-wSP 600 µg Only treatment groups.</description>
          </group>
          <group group_id="O4">
            <title>Combined Control (600 µg)</title>
            <description>All participants enrolled during Cohort 2 who received booster-only or no intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Streptococcus Pneumoniae Serotype NT4b in the Nasopharynx</title>
          <description>Nasopharyngeal samples were further analyzed for the prevalence of specific Streptococcus pneumoniae serotypes by microarray. The number of participants with a positive result for SPn serotype NT4b is reported.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
          <population>Nasopharyngeal Carriage (NPC) population with culture-confirmed samples and available serotype data at each time point</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 (Week 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="83"/>
                    <count group_id="O4" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (Week 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="84"/>
                    <count group_id="O4" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (Week 16)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Week 20)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (Week 32)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Density of Streptococcus Pneumoniae Serotype 11A/D/E [11A] in the Nasopharynx</title>
        <description>The density of Streptococcus pneumoniae serotype 11A/D/E [11A] in the nasopharynx was measured by the number of LytA gene copies detected by microarray from nasopharyngeal swabs taken at each study visit.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
        <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
        <population>NPC population with culture-confirmed samples and a relative abundance greater than zero for the serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined PATH-wSP 300 µg</title>
            <description>All participants who received PATH-wSP 300 µg, including participants in the PATH-wSP 300 µg + Booster and participants in the PATH-wSP 300 µg Only treatment groups.</description>
          </group>
          <group group_id="O2">
            <title>Combined Control (300 µg)</title>
            <description>Participants enrolled during Cohort 1 who received booster-only or no intervention.</description>
          </group>
          <group group_id="O3">
            <title>Combined PATH-wSP 600 µg</title>
            <description>All participants who received PATH-wSP 600 µg, including participants in the PATH-wSP 600 µg + Booster and participants in the PATH-wSP 600 µg Only treatment groups.</description>
          </group>
          <group group_id="O4">
            <title>Combined Control (600 µg)</title>
            <description>All participants enrolled during Cohort 2 who received booster-only or no intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Density of Streptococcus Pneumoniae Serotype 11A/D/E [11A] in the Nasopharynx</title>
          <description>The density of Streptococcus pneumoniae serotype 11A/D/E [11A] in the nasopharynx was measured by the number of LytA gene copies detected by microarray from nasopharyngeal swabs taken at each study visit.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
          <population>NPC population with culture-confirmed samples and a relative abundance greater than zero for the serotype.</population>
          <units>log LytA copies</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 (Week 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" lower_limit="10.2" upper_limit="13.6"/>
                    <measurement group_id="O2" value="15.0" lower_limit="9.8" upper_limit="16.7"/>
                    <measurement group_id="O3" value="12.9" lower_limit="3.2" upper_limit="16.7"/>
                    <measurement group_id="O4" value="14" lower_limit="14.0" upper_limit="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (Week 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" lower_limit="7.1" upper_limit="15.3"/>
                    <measurement group_id="O2" value="17.6" lower_limit="11.9" upper_limit="19.7"/>
                    <measurement group_id="O3" value="14.4" lower_limit="12.3" upper_limit="15.7"/>
                    <measurement group_id="O4" value="18.5" lower_limit="18.5" upper_limit="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (Week 16)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" lower_limit="9.4" upper_limit="10.3"/>
                    <measurement group_id="O2" value="13.6" lower_limit="11.5" upper_limit="14.9"/>
                    <measurement group_id="O3" value="16.6" lower_limit="14.7" upper_limit="21.3"/>
                    <measurement group_id="O4" value="14.1" lower_limit="9.0" upper_limit="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Week 20)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1" lower_limit="13.9" upper_limit="22.3"/>
                    <measurement group_id="O2" value="12.3" lower_limit="10.5" upper_limit="13.4"/>
                    <measurement group_id="O3" value="15.8" lower_limit="13.3" upper_limit="20.3"/>
                    <measurement group_id="O4" value="5.4" lower_limit="5.4" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (Week 32)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3" lower_limit="16.1" upper_limit="19.9"/>
                    <measurement group_id="O3" value="14.5" lower_limit="11.1" upper_limit="17.3"/>
                    <measurement group_id="O4" value="16.4" lower_limit="14.5" upper_limit="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Density of Streptococcus Pneumoniae Serotype 13 in the Nasopharynx</title>
        <description>The density of Streptococcus pneumoniae serotype 13 in the nasopharynx was measured by the number of LytA gene copies detected by microarray from nasopharyngeal swabs taken at each study visit.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
        <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
        <population>NPC population with culture-confirmed samples and a relative abundance greater than zero for the serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined PATH-wSP 300 µg</title>
            <description>All participants who received PATH-wSP 300 µg, including participants in the PATH-wSP 300 µg + Booster and participants in the PATH-wSP 300 µg Only treatment groups.</description>
          </group>
          <group group_id="O2">
            <title>Combined Control (300 µg)</title>
            <description>Participants enrolled during Cohort 1 who received booster-only or no intervention.</description>
          </group>
          <group group_id="O3">
            <title>Combined PATH-wSP 600 µg</title>
            <description>All participants who received PATH-wSP 600 µg, including participants in the PATH-wSP 600 µg + Booster and participants in the PATH-wSP 600 µg Only treatment groups.</description>
          </group>
          <group group_id="O4">
            <title>Combined Control (600 µg)</title>
            <description>All participants enrolled during Cohort 2 who received booster-only or no intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Density of Streptococcus Pneumoniae Serotype 13 in the Nasopharynx</title>
          <description>The density of Streptococcus pneumoniae serotype 13 in the nasopharynx was measured by the number of LytA gene copies detected by microarray from nasopharyngeal swabs taken at each study visit.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
          <population>NPC population with culture-confirmed samples and a relative abundance greater than zero for the serotype.</population>
          <units>log LytA copies</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 (Week 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" lower_limit="9.8" upper_limit="15.0"/>
                    <measurement group_id="O2" value="17.1" lower_limit="7.0" upper_limit="17.1"/>
                    <measurement group_id="O3" value="12.2" lower_limit="9.8" upper_limit="13.8"/>
                    <measurement group_id="O4" value="12.3" lower_limit="10.0" upper_limit="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (Week 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" lower_limit="5.1" upper_limit="16.1"/>
                    <measurement group_id="O2" value="11.6" lower_limit="5.7" upper_limit="14.3"/>
                    <measurement group_id="O3" value="15.0" lower_limit="3.0" upper_limit="17.3"/>
                    <measurement group_id="O4" value="12.1" lower_limit="10.3" upper_limit="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (Week 16)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.2" lower_limit="10.7" upper_limit="17.7"/>
                    <measurement group_id="O2" value="15.6" lower_limit="12.9" upper_limit="19.3"/>
                    <measurement group_id="O3" value="17.7" lower_limit="14.0" upper_limit="20.3"/>
                    <measurement group_id="O4" value="13.8" lower_limit="13.8" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Week 20)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2" lower_limit="10.7" upper_limit="16.7"/>
                    <measurement group_id="O2" value="13.1" lower_limit="11.6" upper_limit="14.0"/>
                    <measurement group_id="O3" value="13.4" lower_limit="11.6" upper_limit="18.7"/>
                    <measurement group_id="O4" value="14.6" lower_limit="14.6" upper_limit="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (Week 32)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" lower_limit="11.4" upper_limit="19.0"/>
                    <measurement group_id="O2" value="14.7" lower_limit="10.2" upper_limit="15.1"/>
                    <measurement group_id="O3" value="15.8" lower_limit="10.0" upper_limit="22.3"/>
                    <measurement group_id="O4" value="16.2" lower_limit="13.8" upper_limit="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Density of Streptococcus Pneumoniae Serotype 15A in the Nasopharynx</title>
        <description>The density of Streptococcus pneumoniae serotype 15A in the nasopharynx was measured by the number of LytA gene copies detected by microarray from nasopharyngeal swabs taken at each study visit.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
        <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
        <population>NPC population with culture-confirmed samples and a relative abundance greater than zero for the serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined PATH-wSP 300 µg</title>
            <description>All participants who received PATH-wSP 300 µg, including participants in the PATH-wSP 300 µg + Booster and participants in the PATH-wSP 300 µg Only treatment groups.</description>
          </group>
          <group group_id="O2">
            <title>Combined Control (300 µg)</title>
            <description>Participants enrolled during Cohort 1 who received booster-only or no intervention.</description>
          </group>
          <group group_id="O3">
            <title>Combined PATH-wSP 600 µg</title>
            <description>All participants who received PATH-wSP 600 µg, including participants in the PATH-wSP 600 µg + Booster and participants in the PATH-wSP 600 µg Only treatment groups.</description>
          </group>
          <group group_id="O4">
            <title>Combined Control (600 µg)</title>
            <description>All participants enrolled during Cohort 2 who received booster-only or no intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Density of Streptococcus Pneumoniae Serotype 15A in the Nasopharynx</title>
          <description>The density of Streptococcus pneumoniae serotype 15A in the nasopharynx was measured by the number of LytA gene copies detected by microarray from nasopharyngeal swabs taken at each study visit.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
          <population>NPC population with culture-confirmed samples and a relative abundance greater than zero for the serotype.</population>
          <units>log LytA copies</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 (Week 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7" lower_limit="13.7" upper_limit="13.7"/>
                    <measurement group_id="O3" value="16.1" lower_limit="15.1" upper_limit="17.2"/>
                    <measurement group_id="O4" value="11.0" lower_limit="9.8" upper_limit="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (Week 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" lower_limit="11.3" upper_limit="16.0"/>
                    <measurement group_id="O2" value="13.8" lower_limit="11.2" upper_limit="16.3"/>
                    <measurement group_id="O3" value="18.5" lower_limit="15.6" upper_limit="18.7"/>
                    <measurement group_id="O4" value="16.3" lower_limit="11.7" upper_limit="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (Week 16)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" lower_limit="12.4" upper_limit="17.2"/>
                    <measurement group_id="O2" value="12.3" lower_limit="12.3" upper_limit="12.3"/>
                    <measurement group_id="O3" value="15.8" lower_limit="13.2" upper_limit="16.8"/>
                    <measurement group_id="O4" value="18.9" lower_limit="18.9" upper_limit="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Week 20)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7" lower_limit="11.2" upper_limit="16.8"/>
                    <measurement group_id="O2" value="13.1" lower_limit="13.1" upper_limit="13.1"/>
                    <measurement group_id="O3" value="13.7" lower_limit="11.8" upper_limit="16.2"/>
                    <measurement group_id="O4" value="15.8" lower_limit="13.8" upper_limit="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (Week 32)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0" lower_limit="14.5" upper_limit="19.2"/>
                    <measurement group_id="O2" value="16.3" lower_limit="14.2" upper_limit="21.3"/>
                    <measurement group_id="O3" value="15.2" lower_limit="14.8" upper_limit="15.6"/>
                    <measurement group_id="O4" value="12.9" lower_limit="9.2" upper_limit="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Density of Streptococcus Pneumoniae Serotype 15B/C [15B] in the Nasopharynx</title>
        <description>The density of Streptococcus pneumoniae serotype 15B/C [15B] in the nasopharynx was measured by the number of LytA gene copies detected by microarray from nasopharyngeal swabs taken at each study visit.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
        <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
        <population>NPC population with culture-confirmed samples and a relative abundance greater than zero for the serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined PATH-wSP 300 µg</title>
            <description>All participants who received PATH-wSP 300 µg, including participants in the PATH-wSP 300 µg + Booster and participants in the PATH-wSP 300 µg Only treatment groups.</description>
          </group>
          <group group_id="O2">
            <title>Combined Control (300 µg)</title>
            <description>Participants enrolled during Cohort 1 who received booster-only or no intervention.</description>
          </group>
          <group group_id="O3">
            <title>Combined PATH-wSP 600 µg</title>
            <description>All participants who received PATH-wSP 600 µg, including participants in the PATH-wSP 600 µg + Booster and participants in the PATH-wSP 600 µg Only treatment groups.</description>
          </group>
          <group group_id="O4">
            <title>Combined Control (600 µg)</title>
            <description>All participants enrolled during Cohort 2 who received booster-only or no intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Density of Streptococcus Pneumoniae Serotype 15B/C [15B] in the Nasopharynx</title>
          <description>The density of Streptococcus pneumoniae serotype 15B/C [15B] in the nasopharynx was measured by the number of LytA gene copies detected by microarray from nasopharyngeal swabs taken at each study visit.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
          <population>NPC population with culture-confirmed samples and a relative abundance greater than zero for the serotype.</population>
          <units>log LytA copies</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 (Week 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2" lower_limit="11.5" upper_limit="14.6"/>
                    <measurement group_id="O2" value="10.3" lower_limit="8.7" upper_limit="11.9"/>
                    <measurement group_id="O3" value="12.1" lower_limit="9.8" upper_limit="15.6"/>
                    <measurement group_id="O4" value="14.7" lower_limit="10.9" upper_limit="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (Week 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" lower_limit="10.9" upper_limit="15.0"/>
                    <measurement group_id="O2" value="10.4" lower_limit="8.3" upper_limit="15.8"/>
                    <measurement group_id="O3" value="15.8" lower_limit="14.7" upper_limit="17.2"/>
                    <measurement group_id="O4" value="17.9" lower_limit="16.3" upper_limit="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (Week 16)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7" lower_limit="11.4" upper_limit="15.7"/>
                    <measurement group_id="O2" value="13.5" lower_limit="12.9" upper_limit="16.4"/>
                    <measurement group_id="O3" value="20.0" lower_limit="16.5" upper_limit="20.9"/>
                    <measurement group_id="O4" value="17.3" lower_limit="14.4" upper_limit="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Week 20)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9" lower_limit="11.7" upper_limit="16.4"/>
                    <measurement group_id="O2" value="17.5" lower_limit="14.9" upper_limit="20.2"/>
                    <measurement group_id="O3" value="14.9" lower_limit="11.1" upper_limit="17.2"/>
                    <measurement group_id="O4" value="17.2" lower_limit="12.3" upper_limit="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (Week 32)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" lower_limit="14.8" upper_limit="20.2"/>
                    <measurement group_id="O2" value="17.3" lower_limit="17.3" upper_limit="17.3"/>
                    <measurement group_id="O3" value="11.2" lower_limit="3.7" upper_limit="15.7"/>
                    <measurement group_id="O4" value="12.8" lower_limit="10.6" upper_limit="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Density of Streptococcus Pneumoniae Serotype 19A in the Nasopharynx</title>
        <description>The density of Streptococcus pneumoniae serotype 19A in the nasopharynx was measured by the number of LytA gene copies detected by microarray from nasopharyngeal swabs taken at each study visit.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
        <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
        <population>NPC population with culture-confirmed samples and a relative abundance greater than zero for the serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined PATH-wSP 300 µg</title>
            <description>All participants who received PATH-wSP 300 µg, including participants in the PATH-wSP 300 µg + Booster and participants in the PATH-wSP 300 µg Only treatment groups.</description>
          </group>
          <group group_id="O2">
            <title>Combined Control (300 µg)</title>
            <description>Participants enrolled during Cohort 1 who received booster-only or no intervention.</description>
          </group>
          <group group_id="O3">
            <title>Combined PATH-wSP 600 µg</title>
            <description>All participants who received PATH-wSP 600 µg, including participants in the PATH-wSP 600 µg + Booster and participants in the PATH-wSP 600 µg Only treatment groups.</description>
          </group>
          <group group_id="O4">
            <title>Combined Control (600 µg)</title>
            <description>All participants enrolled during Cohort 2 who received booster-only or no intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Density of Streptococcus Pneumoniae Serotype 19A in the Nasopharynx</title>
          <description>The density of Streptococcus pneumoniae serotype 19A in the nasopharynx was measured by the number of LytA gene copies detected by microarray from nasopharyngeal swabs taken at each study visit.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
          <population>NPC population with culture-confirmed samples and a relative abundance greater than zero for the serotype.</population>
          <units>log LytA copies</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 (Week 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" lower_limit="6.4" upper_limit="15.7"/>
                    <measurement group_id="O2" value="12.9" lower_limit="8.7" upper_limit="15.2"/>
                    <measurement group_id="O3" value="12.3" lower_limit="11.4" upper_limit="14.6"/>
                    <measurement group_id="O4" value="11.0" lower_limit="7.4" upper_limit="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (Week 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.2" lower_limit="5.2" upper_limit="15.3"/>
                    <measurement group_id="O2" value="12.3" lower_limit="9.9" upper_limit="13.5"/>
                    <measurement group_id="O3" value="16.9" lower_limit="11.3" upper_limit="18.6"/>
                    <measurement group_id="O4" value="15.5" lower_limit="11.4" upper_limit="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (Week 16)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1" lower_limit="15.1" upper_limit="15.1"/>
                    <measurement group_id="O2" value="10.6" lower_limit="7.0" upper_limit="16.0"/>
                    <measurement group_id="O3" value="16.7" lower_limit="13.2" upper_limit="17.7"/>
                    <measurement group_id="O4" value="14.6" lower_limit="13.6" upper_limit="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Week 20)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.1" lower_limit="16.0" upper_limit="20.2"/>
                    <measurement group_id="O2" value="15.3" lower_limit="8.7" upper_limit="18.2"/>
                    <measurement group_id="O3" value="13.3" lower_limit="12.0" upper_limit="17.0"/>
                    <measurement group_id="O4" value="14.9" lower_limit="7.8" upper_limit="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (Week 32)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0" lower_limit="13.7" upper_limit="19.2"/>
                    <measurement group_id="O2" value="15.2" lower_limit="13.0" upper_limit="22.4"/>
                    <measurement group_id="O3" value="12.2" lower_limit="5.4" upper_limit="16.8"/>
                    <measurement group_id="O4" value="12.9" lower_limit="5.8" upper_limit="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Density of Streptococcus Pneumoniae Serotype 19F in the Nasopharynx</title>
        <description>The density of Streptococcus pneumoniae serotype 19F in the nasopharynx was measured by the number of LytA gene copies detected by microarray from nasopharyngeal swabs taken at each study visit.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
        <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
        <population>NPC population with culture-confirmed samples and a relative abundance greater than zero for the serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined PATH-wSP 300 µg</title>
            <description>All participants who received PATH-wSP 300 µg, including participants in the PATH-wSP 300 µg + Booster and participants in the PATH-wSP 300 µg Only treatment groups.</description>
          </group>
          <group group_id="O2">
            <title>Combined Control (300 µg)</title>
            <description>Participants enrolled during Cohort 1 who received booster-only or no intervention.</description>
          </group>
          <group group_id="O3">
            <title>Combined PATH-wSP 600 µg</title>
            <description>All participants who received PATH-wSP 600 µg, including participants in the PATH-wSP 600 µg + Booster and participants in the PATH-wSP 600 µg Only treatment groups.</description>
          </group>
          <group group_id="O4">
            <title>Combined Control (600 µg)</title>
            <description>All participants enrolled during Cohort 2 who received booster-only or no intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Density of Streptococcus Pneumoniae Serotype 19F in the Nasopharynx</title>
          <description>The density of Streptococcus pneumoniae serotype 19F in the nasopharynx was measured by the number of LytA gene copies detected by microarray from nasopharyngeal swabs taken at each study visit.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
          <population>NPC population with culture-confirmed samples and a relative abundance greater than zero for the serotype.</population>
          <units>log LytA copies</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 (Week 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" lower_limit="13.4" upper_limit="16.4"/>
                    <measurement group_id="O2" value="12.2" lower_limit="10.6" upper_limit="13.8"/>
                    <measurement group_id="O3" value="12.7" lower_limit="11.1" upper_limit="16.2"/>
                    <measurement group_id="O4" value="12.9" lower_limit="12.3" upper_limit="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (Week 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" lower_limit="12.1" upper_limit="17.8"/>
                    <measurement group_id="O2" value="13.7" lower_limit="13.0" upper_limit="15.3"/>
                    <measurement group_id="O3" value="12.2" lower_limit="11.6" upper_limit="17.5"/>
                    <measurement group_id="O4" value="18.2" lower_limit="10.1" upper_limit="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (Week 16)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" lower_limit="10.2" upper_limit="17.7"/>
                    <measurement group_id="O2" value="13.0" lower_limit="11.8" upper_limit="17.9"/>
                    <measurement group_id="O3" value="16.1" lower_limit="14.4" upper_limit="17.4"/>
                    <measurement group_id="O4" value="9.9" lower_limit="5.8" upper_limit="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Week 20)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" lower_limit="5.4" upper_limit="15.4"/>
                    <measurement group_id="O2" value="14.9" lower_limit="11.5" upper_limit="19.7"/>
                    <measurement group_id="O3" value="16.7" lower_limit="13.9" upper_limit="17.9"/>
                    <measurement group_id="O4" value="11.1" lower_limit="10.1" upper_limit="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (Week 32)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" lower_limit="10.6" upper_limit="17.8"/>
                    <measurement group_id="O2" value="17.7" lower_limit="7.7" upper_limit="17.9"/>
                    <measurement group_id="O3" value="15.3" lower_limit="13.7" upper_limit="17.1"/>
                    <measurement group_id="O4" value="14.1" lower_limit="13.3" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Density of Streptococcus Pneumoniae Serotype 3 in the Nasopharynx</title>
        <description>The density of Streptococcus pneumoniae serotype 3 in the nasopharynx was measured by the number of LytA gene copies detected by microarray from nasopharyngeal swabs taken at each study visit.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
        <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
        <population>NPC population with culture-confirmed samples and a relative abundance greater than zero for the serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined PATH-wSP 300 µg</title>
            <description>All participants who received PATH-wSP 300 µg, including participants in the PATH-wSP 300 µg + Booster and participants in the PATH-wSP 300 µg Only treatment groups.</description>
          </group>
          <group group_id="O2">
            <title>Combined Control (300 µg)</title>
            <description>Participants enrolled during Cohort 1 who received booster-only or no intervention.</description>
          </group>
          <group group_id="O3">
            <title>Combined PATH-wSP 600 µg</title>
            <description>All participants who received PATH-wSP 600 µg, including participants in the PATH-wSP 600 µg + Booster and participants in the PATH-wSP 600 µg Only treatment groups.</description>
          </group>
          <group group_id="O4">
            <title>Combined Control (600 µg)</title>
            <description>All participants enrolled during Cohort 2 who received booster-only or no intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Density of Streptococcus Pneumoniae Serotype 3 in the Nasopharynx</title>
          <description>The density of Streptococcus pneumoniae serotype 3 in the nasopharynx was measured by the number of LytA gene copies detected by microarray from nasopharyngeal swabs taken at each study visit.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
          <population>NPC population with culture-confirmed samples and a relative abundance greater than zero for the serotype.</population>
          <units>log LytA copies</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 (Week 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" lower_limit="10.7" upper_limit="14.2"/>
                    <measurement group_id="O2" value="11.1" lower_limit="3.7" upper_limit="14.7"/>
                    <measurement group_id="O3" value="9.7" lower_limit="8.3" upper_limit="15.6"/>
                    <measurement group_id="O4" value="12.4" lower_limit="7.7" upper_limit="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (Week 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.2" lower_limit="10.9" upper_limit="18.6"/>
                    <measurement group_id="O2" value="11.0" lower_limit="8.4" upper_limit="14.3"/>
                    <measurement group_id="O3" value="16.4" lower_limit="13.5" upper_limit="17.9"/>
                    <measurement group_id="O4" value="13.3" lower_limit="13.3" upper_limit="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (Week 16)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9" lower_limit="11.2" upper_limit="15.7"/>
                    <measurement group_id="O2" value="12.7" lower_limit="11.3" upper_limit="15.9"/>
                    <measurement group_id="O3" value="15.2" lower_limit="14.1" upper_limit="16.7"/>
                    <measurement group_id="O4" value="15.4" lower_limit="14.8" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Week 20)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" lower_limit="10.9" upper_limit="17.5"/>
                    <measurement group_id="O2" value="14.1" lower_limit="11.8" upper_limit="15.5"/>
                    <measurement group_id="O3" value="14.7" lower_limit="13.6" upper_limit="19.4"/>
                    <measurement group_id="O4" value="17.9" lower_limit="12.5" upper_limit="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (Week 32)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" lower_limit="12.0" upper_limit="19.7"/>
                    <measurement group_id="O2" value="14.2" lower_limit="11.4" upper_limit="17.0"/>
                    <measurement group_id="O3" value="13.6" lower_limit="11.0" upper_limit="17.4"/>
                    <measurement group_id="O4" value="16.6" lower_limit="16.6" upper_limit="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Density of Streptococcus Pneumoniae Serotype 35B in the Nasopharynx</title>
        <description>The density of Streptococcus pneumoniae serotype 35B in the nasopharynx was measured by the number of LytA gene copies detected by microarray from nasopharyngeal swabs taken at each study visit.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
        <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
        <population>NPC population with culture-confirmed samples and a relative abundance greater than zero for the serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined PATH-wSP 300 µg</title>
            <description>All participants who received PATH-wSP 300 µg, including participants in the PATH-wSP 300 µg + Booster and participants in the PATH-wSP 300 µg Only treatment groups.</description>
          </group>
          <group group_id="O2">
            <title>Combined Control (300 µg)</title>
            <description>Participants enrolled during Cohort 1 who received booster-only or no intervention.</description>
          </group>
          <group group_id="O3">
            <title>Combined PATH-wSP 600 µg</title>
            <description>All participants who received PATH-wSP 600 µg, including participants in the PATH-wSP 600 µg + Booster and participants in the PATH-wSP 600 µg Only treatment groups.</description>
          </group>
          <group group_id="O4">
            <title>Combined Control (600 µg)</title>
            <description>All participants enrolled during Cohort 2 who received booster-only or no intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Density of Streptococcus Pneumoniae Serotype 35B in the Nasopharynx</title>
          <description>The density of Streptococcus pneumoniae serotype 35B in the nasopharynx was measured by the number of LytA gene copies detected by microarray from nasopharyngeal swabs taken at each study visit.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
          <population>NPC population with culture-confirmed samples and a relative abundance greater than zero for the serotype.</population>
          <units>log LytA copies</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 (Week 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" lower_limit="11.1" upper_limit="16.0"/>
                    <measurement group_id="O2" value="11.1" lower_limit="8.5" upper_limit="13.0"/>
                    <measurement group_id="O3" value="13.1" lower_limit="10.8" upper_limit="14.7"/>
                    <measurement group_id="O4" value="12.3" lower_limit="11.2" upper_limit="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (Week 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" lower_limit="9.0" upper_limit="15.1"/>
                    <measurement group_id="O2" value="9.1" lower_limit="8.4" upper_limit="17.8"/>
                    <measurement group_id="O3" value="14.0" lower_limit="9.7" upper_limit="17.2"/>
                    <measurement group_id="O4" value="14.3" lower_limit="11.7" upper_limit="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (Week 16)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" lower_limit="8.3" upper_limit="15.5"/>
                    <measurement group_id="O2" value="15.5" lower_limit="13.1" upper_limit="18.4"/>
                    <measurement group_id="O3" value="15.3" lower_limit="12.1" upper_limit="19.3"/>
                    <measurement group_id="O4" value="19.3" lower_limit="17.9" upper_limit="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Week 20)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" lower_limit="2.0" upper_limit="15.3"/>
                    <measurement group_id="O2" value="16.8" lower_limit="12.4" upper_limit="18.5"/>
                    <measurement group_id="O3" value="12.8" lower_limit="11.4" upper_limit="15.4"/>
                    <measurement group_id="O4" value="11.7" lower_limit="1.5" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (Week 32)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" lower_limit="10.2" upper_limit="18.0"/>
                    <measurement group_id="O2" value="13.4" lower_limit="12.8" upper_limit="18.4"/>
                    <measurement group_id="O3" value="14.5" lower_limit="11.3" upper_limit="16.4"/>
                    <measurement group_id="O4" value="12.2" lower_limit="12.2" upper_limit="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Density of Streptococcus Pneumoniae Serotype 6A/B [6A] in the Nasopharynx</title>
        <description>The density of Streptococcus pneumoniae serotype 6A/B [6A] in the nasopharynx was measured by the number of LytA gene copies detected by microarray from nasopharyngeal swabs taken at each study visit.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
        <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
        <population>NPC population with culture-confirmed samples and a relative abundance greater than zero for the serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined PATH-wSP 300 µg</title>
            <description>All participants who received PATH-wSP 300 µg, including participants in the PATH-wSP 300 µg + Booster and participants in the PATH-wSP 300 µg Only treatment groups.</description>
          </group>
          <group group_id="O2">
            <title>Combined Control (300 µg)</title>
            <description>Participants enrolled during Cohort 1 who received booster-only or no intervention.</description>
          </group>
          <group group_id="O3">
            <title>Combined PATH-wSP 600 µg</title>
            <description>All participants who received PATH-wSP 600 µg, including participants in the PATH-wSP 600 µg + Booster and participants in the PATH-wSP 600 µg Only treatment groups.</description>
          </group>
          <group group_id="O4">
            <title>Combined Control (600 µg)</title>
            <description>All participants enrolled during Cohort 2 who received booster-only or no intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Density of Streptococcus Pneumoniae Serotype 6A/B [6A] in the Nasopharynx</title>
          <description>The density of Streptococcus pneumoniae serotype 6A/B [6A] in the nasopharynx was measured by the number of LytA gene copies detected by microarray from nasopharyngeal swabs taken at each study visit.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
          <population>NPC population with culture-confirmed samples and a relative abundance greater than zero for the serotype.</population>
          <units>log LytA copies</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 (Week 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" lower_limit="7.1" upper_limit="17.6"/>
                    <measurement group_id="O2" value="12.4" lower_limit="9.0" upper_limit="14.5"/>
                    <measurement group_id="O3" value="13.4" lower_limit="11.4" upper_limit="14.3"/>
                    <measurement group_id="O4" value="11.6" lower_limit="10.1" upper_limit="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (Week 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="13.2" upper_limit="18.9"/>
                    <measurement group_id="O2" value="12.6" lower_limit="8.1" upper_limit="14.6"/>
                    <measurement group_id="O3" value="14.7" lower_limit="9.6" upper_limit="17.2"/>
                    <measurement group_id="O4" value="15.8" lower_limit="1.5" upper_limit="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (Week 16)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" lower_limit="11.9" upper_limit="17.5"/>
                    <measurement group_id="O2" value="15.0" lower_limit="10.6" upper_limit="18.0"/>
                    <measurement group_id="O3" value="14.9" lower_limit="12.3" upper_limit="19.5"/>
                    <measurement group_id="O4" value="14.8" lower_limit="14.8" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Week 20)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5" lower_limit="16.9" upper_limit="21.5"/>
                    <measurement group_id="O2" value="11.7" lower_limit="3.1" upper_limit="12.6"/>
                    <measurement group_id="O3" value="16.6" lower_limit="9.3" upper_limit="17.9"/>
                    <measurement group_id="O4" value="12.7" lower_limit="12.2" upper_limit="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (Week 32)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2" lower_limit="14.7" upper_limit="17.3"/>
                    <measurement group_id="O2" value="14.9" lower_limit="11.4" upper_limit="19.1"/>
                    <measurement group_id="O3" value="14.5" lower_limit="8.3" upper_limit="16.4"/>
                    <measurement group_id="O4" value="12.6" lower_limit="11.3" upper_limit="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Density of Streptococcus Pneumoniae Serotype NT4b in the Nasopharynx</title>
        <description>The density of Streptococcus pneumoniae serotype NT4b in the nasopharynx was measured by the number of LytA gene copies detected by microarray from nasopharyngeal swabs taken at each study visit.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
        <time_frame>Week 0, Week 12, Week 16, Week 20, Week 32</time_frame>
        <population>NPC population with culture-confirmed samples and a relative abundance greater than zero for the serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined PATH-wSP 300 µg</title>
            <description>All participants who received PATH-wSP 300 µg, including participants in the PATH-wSP 300 µg + Booster and participants in the PATH-wSP 300 µg Only treatment groups.</description>
          </group>
          <group group_id="O2">
            <title>Combined Control (300 µg)</title>
            <description>Participants enrolled during Cohort 1 who received booster-only or no intervention.</description>
          </group>
          <group group_id="O3">
            <title>Combined PATH-wSP 600 µg</title>
            <description>All participants who received PATH-wSP 600 µg, including participants in the PATH-wSP 600 µg + Booster and participants in the PATH-wSP 600 µg Only treatment groups.</description>
          </group>
          <group group_id="O4">
            <title>Combined Control (600 µg)</title>
            <description>All participants enrolled during Cohort 2 who received booster-only or no intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Density of Streptococcus Pneumoniae Serotype NT4b in the Nasopharynx</title>
          <description>The density of Streptococcus pneumoniae serotype NT4b in the nasopharynx was measured by the number of LytA gene copies detected by microarray from nasopharyngeal swabs taken at each study visit.
NPC endpoints were analyzed within combined study groups:
PATH-wSP 300 µg: Combines groups who received 300 µg PATH-wSP with or without booster
Control (300 µg): Participants in VAC-010 Cohort 1 who received booster-only, plus non-interventional group enrolled during Cohort 1
PATH-wSP 600 µg: Combines groups who received 600 µg PATH-wSP with or without booster
Control (600 µg): Participants in VAC-010 Cohort 2 who received booster-only, plus non-interventional group enrolled during Cohort 2</description>
          <population>NPC population with culture-confirmed samples and a relative abundance greater than zero for the serotype.</population>
          <units>log LytA copies</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 (Week 0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="27"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" lower_limit="8.5" upper_limit="13.7"/>
                    <measurement group_id="O2" value="9.8" lower_limit="8.2" upper_limit="12.5"/>
                    <measurement group_id="O3" value="10.7" lower_limit="9.9" upper_limit="13.1"/>
                    <measurement group_id="O4" value="11.7" lower_limit="9.4" upper_limit="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (Week 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" lower_limit="9.1" upper_limit="14.8"/>
                    <measurement group_id="O2" value="12.2" lower_limit="9.8" upper_limit="12.9"/>
                    <measurement group_id="O3" value="13.4" lower_limit="12.4" upper_limit="14.9"/>
                    <measurement group_id="O4" value="12.1" lower_limit="7.7" upper_limit="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (Week 16)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" lower_limit="9.8" upper_limit="13.7"/>
                    <measurement group_id="O2" value="12.1" lower_limit="9.7" upper_limit="14.5"/>
                    <measurement group_id="O3" value="13.7" lower_limit="11.2" upper_limit="14.5"/>
                    <measurement group_id="O4" value="13.7" lower_limit="11.1" upper_limit="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Week 20)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" lower_limit="10.0" upper_limit="14.3"/>
                    <measurement group_id="O2" value="9.6" lower_limit="8.5" upper_limit="12.0"/>
                    <measurement group_id="O3" value="12.1" lower_limit="10.1" upper_limit="13.6"/>
                    <measurement group_id="O4" value="11.5" lower_limit="9.7" upper_limit="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (Week 32)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.2" lower_limit="12.9" upper_limit="16.6"/>
                    <measurement group_id="O2" value="11.7" lower_limit="9.8" upper_limit="13.2"/>
                    <measurement group_id="O3" value="12.1" lower_limit="9.1" upper_limit="13.3"/>
                    <measurement group_id="O4" value="12.2" lower_limit="10.5" upper_limit="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>32 weeks; for participants enrolled concurrently in Study VAC-010 adverse events were collected after the last VAC-010 visit through to Week 32.</time_frame>
      <desc>The AEs collected in this non-interventional study were those that remained open after the last visit in the VAC-010 Study, those attributed to study vaccine in VAC-010 with onset after the participant exited VAC-010, those that were related to a VAC-011 procedure (i.e. blood draw, nasal swab sample), and all serious adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>PATH-wSP 300 µg + Booster</title>
          <description>Toddlers who enrolled in Cohort 1 of Study VAC-010 and received 300 µg PATH-wSP plus the two booster vaccines (Synflorix and Pentavac) followed by a 2nd injection of 300 µg PATH-wSP 8 weeks later.</description>
        </group>
        <group group_id="E2">
          <title>PATH-wSP 300 µg Only</title>
          <description>Toddlers who enrolled in Cohort 1 of Study VAC-010 and received 300 µg PATH-wSP and 2 saline injections followed by a 2nd injection of 300 µg PATH-wSP 8 weeks later.</description>
        </group>
        <group group_id="E3">
          <title>PATH-wSP 600 µg + Booster</title>
          <description>Toddlers who enrolled in Cohort 2 of Study VAC-010 and received 600 µg PATH-wSP plus the two booster vaccines (Synflorix and Pentavac) followed by a 2nd injection of 600 µg PATH-wSP 8 weeks later.</description>
        </group>
        <group group_id="E4">
          <title>PATH-wSP 600 µg Only</title>
          <description>Toddlers who enrolled in Cohort 2 of Study VAC-010 and received 600 µg PATH-wSP and 2 saline injections followed by a 2nd injection of 600 µg PATH-wSP 8 weeks later.</description>
        </group>
        <group group_id="E5">
          <title>Booster Only (Both Cohorts)</title>
          <description>Toddlers who enrolled in Cohort 1 or Cohort 2 of Study VAC-010 and received one saline injection and the two booster vaccines (Synflorix and Pentavac) followed by a 2nd saline injection 8 weeks later.</description>
        </group>
        <group group_id="E6">
          <title>No Intervention</title>
          <description>Toddlers who enrolled during Cohort 1 or Cohort 2 who did not participate in Study VAC-010 and did not receive either PATH-wSP or either of the booster vaccines (Pentavac or Synflorix).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (15.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cerebral malaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (15.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jorge Flores</name_or_title>
      <organization>PATH</organization>
      <phone>(202) 822-0033</phone>
      <email>jeflores@path.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

